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Abstract
Gas vesicles are a unique class of gas-filled protein nanostructures whose physical properties 
allow them to serve as highly sensitive imaging agents for ultrasound and magnetic resonance 
imaging (MRI), detectable at sub-nanomolar concentrations. Here we provide a protocol for 
isolating gas vesicles from native and heterologous host organisms, functionalizing these 
nanostructures with moieties for targeting and fluorescence, characterizing their biophysical 
properties and imaging them using ultrasound and magnetic resonance imaging. Gas vesicles can 
be isolated from natural cyanobacterial and haloarchaeal host organisms or from E. coli expressing 
a heterologous gas vesicle gene cluster, and purified using buoyancy-assisted techniques. They can 
then be modified by replacing surface-bound proteins with engineered, heterologously expressed 
variants, or through chemical conjugation, resulting in altered mechanical, surface and targeting 
properties. Pressurized absorbance spectroscopy is used to characterize their mechanical 
properties, while dynamic light scattering and transmission electron microscopy are used to 
determine nanoparticle size and morphology, respectively. Gas vesicles can then be imaged with 
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ultrasound in vitro and in vivo using pulse sequences optimized for their detection versus 
background. They can also be imaged with hyperpolarized xenon MRI using chemical exchange 
saturation transfer between gas vesicle-bound and dissolved xenon – a technique currently 
implemented in vitro. Taking 3–8 days to prepare, these genetically encodable nanostructures 
enable multi-modal, noninvasive biological imaging with high sensitivity and potential for 
molecular targeting.
EDITORIAL SUMMARY
The physical properties of a unique class of proteins called gas vesicles allow them to be used as 
contrast agents for ultrasound and magnetic resonance imaging (MRI). This protocol describes 
how to isolate gas vesicles, functionalize them with moieties for targeting and fluorescence, and 
image them in vitro and in vivo.
Keywords
Gas vesicles; protein nanostructures; noninvasive imaging; contrast agents; molecular reporters; 
ultrasound; hyperpolarized MRI; magnetic resonance imaging; acoustics
INTRODUCTION
The study of biological function and disease and the development of clinical diagnostics 
require technologies for noninvasive imaging of cells and molecules in intact organisms. 
Ultrasound and magnetic resonance imaging (MRI) are two widely used noninvasive 
imaging modalities that provide high spatial and temporal resolution but are currently 
restricted in their molecular imaging capabilities due to limited repertoires of nanoscale 
contrast agents. For ultrasound, conventional imaging agents based on microbubbles – 
micron-sized particles of trapped gas stabilized by a lipid or protein shell – are limited by 
their size and physical instability to labeling the vasculature and endovascular targets,. 
Conventional MRI contrast agents based on superparamagnetic iron oxides, or lanthanide 
chelates are limited by their potential toxicity and the requirement that they be present at 
relatively high concentrations (typically in the μM range) for detection by MRI .
Development of the Protocol
To develop biomolecular imaging agents addressing the aforementioned limitations, we 
recently introduced a new class of molecular imaging agents for ultrasound and MRI based 
on gas vesicles (GVs) – genetically encoded gas-filled protein nanostructures from buoyant 
photosynthetic microorganisms,. GVs comprise a protein shell with spatial dimensions of 
~200 nm and thickness of ~2 nm enclosing a hollow gas-filled interior. Gas dissolved in the 
surrounding media partitions freely in and out of this nanoscale compartment, while liquid 
water is excluded by the shell’s hydrophobic inner surface. Microbes such as the 
cyanobaterium Anabaena flosaquae (Ana) and the archaeon Halobacteria salinarum (Halo) 
form GVs as a means to regulate cellular buoyancy for optimal access to light and nutrients. 
In these organisms, GVs are encoded by operons of 8–14 genes, which include the primary 
structural proteins GvpA and GvpC and several minor constituents and chaperones.
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We recently discovered that GVs purified from cyanobacteria and haloarchaea scatter sound 
waves and thereby produce ultrasound contrast at sub-nanomolar concentrations. 
Furthermore, we found that GVs’ unique physical properties enable them to produce 
harmonic ultrasound signals useful for contrast specificity in vitro and in vivo,. We also 
showed that GVs from different species can be imaged in multiplex based on their 
differential responses to acoustic pressure, and that conditional GV clustering leads to 
contrast enhancement, allowing them to be used as molecular sensors. In parallel, we 
demonstrated that GVs produce contrast in hyperpolarized xenon MRI, an emerging form of 
imaging that takes advantage of non-equilibrium spin polarization to increase molecular 
sensitivity by factors of up to 105. We discovered that atoms of hyperpolarized 129Xe 
dissolved in aqueous media exchange in and out of the GV interior, where their distinct 
chemical shift enables amplified MRI contrast to be produced using chemical exchange 
saturation transfer (CEST) pulse sequences. Using this hyperpolarized CEST (HyperCEST) 
technique allows GVs to be detected at picomolar concentrations. In addition, the distinct 
chemical shifts of GVs in different microbial species enable multiplexed imaging. 
HyperCEST is currently performed in vitro, but is advancing toward in vivo use,.
One particularly promising aspect of GVs is the possibility of engineering their physical and 
biochemical properties at the genetic level. To take advantage of this possibility, we recently 
developed a convenient genetic engineering platform, in which a single target protein, GvpC, 
on the surface of GVs purified from Ana cells is replaced by heterologously expressed 
engineered versions. This strategy allows the modification of GV mechanical properties, 
including their harmonic response to sound waves and collapse under pressure for enhanced 
contrast and multiplexed imaging. In addition, genetic modification enables surface display 
of peptides such as lysine-rich protein to modify surface charge, CD47 to minimize uptake 
by macrophages, polyarginine for cellular internalization and RGD for targeting to integrin 
receptors on tumor cells.
Overview of the Procedure
Here, we present a detailed optimized protocol to express and purify GVs (Steps 1|(A-C)) 
and quantify (Steps 2–3), functionalize and genetically engineer them (Steps 4–45), 
characterize their size and shape (Steps 46|(A-C)), and use them as contrast agents for non-
invasive imaging applications (Steps 47–98). As illustrated in Figure 1, the procedure begins 
with isolation of GVs from cultures of Ana and Halo, or from E. coli expressing a 
heterologous GV gene cluster from Bacillus megaterium (Mega) (note that the Mega GVs 
were referred to as E. coli GVs in the cited paper). This results in three nanostructure 
populations with distinct properties (Table 1). These GVs are then quantified and 
characterized using pressure-dependent spectroscopy, dynamic light scattering (DLS) and 
transmission electron microscopy (TEM). Protocols for modification and functionalization 
using genetic and chemical approaches are provided as an added option based on the desired 
end application. Finally, the GVs are imaged in vitro and in vivo using ultrasound and in 
vitro using HyperCEST MRI.
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Advantages and Limitations:
Among the properties that make GVs attractive as imaging agents are their nanometer size, 
their fundamental physical stability, their biocompatibility as particles made entirely of 
protein, and their lack of requirement for metals or other inorganic cofactors to produce 
image contrast. In addition, as the first genetically encodable contrast agents for ultrasound 
and hyperpolarized xenon MRI, they offer the possibility of being developed as reporter 
genes, creating new opportunities for non-invasive imaging at the molecular and cellular 
level.
Among the limitations of GVs in molecular imaging applications are their lower 
echogenicity per particle compared to conventional microbubble contrast agents for 
ultrasound and the specialized hyperpolarized Xe approach currently needed to take 
advantage of their sensitivity as reporters for MRI. In addition, the modular engineering 
approach presented here is done in vitro on purified GVs, and future efforts will focus on 
extending this platform to engineering of these nanostructures completely within cells. 
Furthermore, the use of GVs as dynamic molecular sensors based on conditional clustering 
requires ascertaining that a given molecular design does not result in non-specific 
aggregation, which must be done on a case-by-case basis.
EXPERIMENTAL DESIGN:
Here, we describe key experimental parameters for each stage of the protocol. One important 
initial consideration is the choice of GV-producing species. Although this protocol presents 
methods for producing three different types of GVs – Ana, Halo and Mega – one of these 
types may be most appropriate for a given application (see Table 1). For ultrasound, 
unmodified Halo GVs can be used directly in ultrasound imaging to obtain non-linear 
signals,. Ana GVs are the system of choice if one wishes to genetically tune the properties of 
GVs for multiplexing, multimodal imaging and targeting applications,. Mega GVs produce 
lower echogenicity under ultrasound compared to Ana and Halo GVs (Figure S1, a-d), but 
have a higher critical collapse pressure that may make them useful for multiplexing. Halo 
GVs produce non-linear ultrasound contrast immediately after purification, while Ana GVs 
require a chemical treatment. With regard to Xe-MRI, Ana and Mega GVs are more stable 
under pressure and during the bubbling of hyperpolarized xenon (as described below) 
compared to Halo GVs. All three species have a unique chemical shift in Xe-MRI, allowing 
multiplexing.
Production and Purification of Gas Vesicles (GVs):
GVs are obtained from Ana, Halo or heterologously-expressing E. coli. Ana is a green, 
filamentous cyanobacterium that naturally inhabits fresh water lakes. Halo is a pink 
halophilic and thermophilic archaea that grows in salt-water ponds. Ana is cultured in low-
salinity medium supplemented with trace metals and buffering agents, while Halo is cultured 
in high salinity medium for GV production.
Ana and Halo cultures natively produce ample GVs after a few weeks of growth,,. Ana 
cultures additionally require a controlled gaseous environment and illumination for optimal 
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growth (Figure 2a-b). A freshly inoculated culture of cells may require several rounds 
(typically 2–3) of subculture to become strongly proliferative (Figure 2c-d). The confluent 
culture of microbes is then transferred to a separatory funnel that is left undisturbed for up to 
a week to allow the buoyant cells producing GVs to float to the top and separate from media 
(Figure 2e-f). Buoyant cells are then lysed using hyper-osmotic shock for Ana and hypo-
osmotic shock for Halo. Subsequently, centrifugally assisted floatation is used to isolate 
GVs from the cell lysate to yield a concentrated, milky-white solution of GVs in the buffer 
of choice,, (Figure 2g-j). Heterologous production of Mega GVs in E. coli is accomplished 
by expression from a plasmid encoding a Mega GV gene, followed by detergent-mediated 
lysis.
The procedures leading from inoculation of GV-producing microbes to harvesting and 
purification is summarized in the Table 2, along with important parameters that affect 
processing time, yield and quality.
Growth conditions are chosen to facilitate optimal proliferation of each host strain and GV 
expression. One unusual variable to keep track of is pressure, since GVs collapse 
irreversibly at hydrostatic pressures of 50 to 800 kPa, depending on species. For example, 
the cultures should be grown under mild agitation, as excessive shaking may lead to GV 
collapse. During centrifugation steps, it is necessary to calculate the hydrostatic pressure 
generated for a particular g-force on the liquid column of GVs and ensure that it is well 
below the GV critical collapse pressure. Long-term storage of purified GV stocks should 
preferably be done in screw-top vials, as micro-centrifuge tubes with snap-lock caps may 
cause GV collapse due to pressurization of the sample while opening or closing the tube.
Quantification and Characterization of GVs:
Purified GVs resuspended in the buffer of choice (e.g. phosphate buffered saline, PBS) can 
be quantified by measuring the optical density at 500 nm, or OD500, since GVs scatter 
visible light (Step 2). Collapsed GVs (in the same buffer), which do not scatter light, are 
typically used as the blank control for measurements, yielding a pressure-sensitive OD 
reading (OD500, ps). It is important to note that clustering of GVs, whether by design or due 
to functionalization with aggregation-prone moieties can confound OD500 measurements 
and contribute to errors in calculating concentration from OD500. Pressurized absorbance 
spectroscopy assays GV mechanical strength by measuring OD500 under increasing 
hydrostatic pressure using the device described in the Equipment Setup section (Figure 3) 
and the protocol described in Steps 46|(A)(i-ix).
Dynamic light scattering (DLS) is used to estimate the hydrodynamic size of GVs for 
routine non-destructive characterization and quality control (Steps 46|(B)(i-ii)). DLS can be 
used to assess GV clustering. Care should be taken in the interpretation of DLS readings of 
GVs due to the spherical assumption of the Einstein–Smoluchowski relation and the non-
spherical shape of GVs. Negative contrast TEM is used for imaging GV size, shape, texture 
and integrity following production and physical or biochemical treatments (Steps 46|(C)(i-
viii)). Negative staining with uranyl acetate is used to produce contrast, and use of a buffer 
such as HEPES is preferred over phosphate buffers that may precipitate with the uranyl 
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acetate. The concentration of the GV solution spotted on the grid directly correlates with the 
density of GV particles on the grid.
Modification and Functionalization of GVs:
GVs can be modified and functionalized through genetic and chemical methods. Genetic 
engineering of GV mechanical and surface properties is conveniently performed via 
exchange of the native outer scaffolding protein GvpC (gas vesicle protein C) with 
recombinant GvpC variants (Steps 11–41). For example, fusing short peptides to the termini 
of GvpC allows for cell-specific targeting, and truncated GvpC variants enable acoustic 
multiplexing. GvpC tolerates terminal fusions of peptides up to 100 residues. To covalently 
attach larger proteins, one can use the modular SpyTag-SpyCatcher protein assembly 
system. GVs reconstituted with SpyTag-GvpC can be reacted with proteins of interest fused 
to SpyCatcher, forming a covalent bond (Steps 42–45).
Chemical conjugation to GVs makes use of lysine residues on their protein shells and 
amine-reactive crosslinkers such as sulfo-N-hydroxysuccinimide esters (Sulfo-NHS). 
Chemical moieties including polymers (e.g. polyethylene glycol), fluorophores and small 
molecules (e.g. biotin) can be conjugated using this method (Steps 4–10). Biotinylated GVs 
can subsequently react with streptavidin or avidinated antibodies. The Sulfo-NHS coupling 
reaction can be conducted in PBS (pH 7.4) as a one-pot reaction. Depending on the 
application, the desired extent of labeling can be tuned by varying the molar ratio of Sulfo-
NHS to GVs and by changing the incubation time. Either dialysis or buoyancy purification 
can be used to separate the labeled GVs from excess reactants.
Ultrasound Imaging of GVs:
For in vitro imaging, GVs can be embedded and imaged in multi-well agarose phantoms 
(Figure 4a, Steps 47–62). A typical experimental setup for in vitro and in vivo ultrasound 
imaging is shown in Figure 4, a-d. Experimental design parameters include phantom 
composition, (i.e. percentage of agarose, buffer, background scattering particles), 
concentration and amount of GV sample loaded. Phantom molds can be made using 3-D 
printing to obtain defined well size, shape and spacing. Imaging parameters include plane of 
imaging (longitudinal versus transverse cross-section of the phantom wells), mode of 
ultrasound imaging (conventional or nonlinear imaging), transducer frequency range, 
transmit waveform characteristics such as pulse envelope shape, number of cycles, 
amplitude and frequency. Importantly, the amplitude used for imaging must be below the 
GVs’ acoustic critical collapse pressure. PBS is typically used as a negative control for 
ultrasound contrast and 5 μm polystyrene beads that scatter linearly at medical ultrasound 
frequencies are used as a reference sample. All GV samples and controls are mixed with 
melted agarose solution prior to loading. Solidification of the agarose after loading into the 
phantom wells ensures that samples are uniformly distributed throughout the well and that 
GVs remain suspended in the agarose matrix without floating during imaging. Typically, a 
final OD500 of 2.25 for Ana GVs and 0.4% (wt/vol) for polystyrene beads is used to match 
echogenicity. For Halo GVs, a final OD of 0.5 gives good signal without attenuation, with 
0.83% (wt/vol) polystyrene beads to match echogenicity. In-situ collapse of GVs using 
pulses with amplitudes above the GVs’ acoustic critical collapse pressures cause GV 
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ultrasound signals to disappear, allowing confirmation of GV-based signals and background 
subtraction. In addition, differential collapse at multiple pressures and spectral unmixing 
allow multiplexed imaging of mechanically distinct GV classes. Quantification of signals in 
ultrasound images is typically performed using MATLAB or ImageJ software.
The in vivo ultrasound imaging protocol has been used to look at GV passage through the 
inferior vena cava (IVC) and subsequent induced contrast enhancement in the liver after 
intravenous injection, (Step 63|(A-B)), but can be adapted for other organs or tissues. 
Depending on the tissue region of interest, some ultrasound imaging parameters, such as 
image gain and field of view may need to be adjusted accordingly. As in in vitro imaging, it 
is critical that the transmit power is kept at a value that provides sufficient signal without 
collapsing the GVs. Further adjustments can be made to GV solution concentration and 
volume, according to experimental needs. Functionalized GVs can also be imaged using this 
protocol, as long as appropriate controls are used. When planning an imaging experiment 
using functionalized GVs, we suggest using native GVs from the same batch as a control. It 
is possible to administer multiple injections of GVs in the same mouse, as long as the total 
injection volume does not exceed the limit stated in institutional guidelines. If required, GV 
solutions can be tested for bacterial endotoxins using quantitative, chromogenic endpoint 
LAL assays, such as the QCL-1000™ Assay (Lonza). Endotoxins can be removed using 
commercially available affinity resins such as the ToxinEraser™ Endotoxin Removal Resin 
(GenScript). Once injected, ensure GVs have cleared completely and tissue contrast signal is 
back to baseline before a second bolus injection.
129Xe MRI Imaging of GVs:
Hyperpolarized 129Xe-MRI is an active area of molecular imaging research, which is 
currently mainly performed in vitro with pure contrast agents or labeled cells,, while in vivo 
techniques are being developed,. This protocol describes the imaging of GVs using 
hyperpolarized 129Xe MRI in vitro, as previously done with purified GVs, GV-expressing 
cells and GV-labeled cells. This involves preparing the hyperpolarized gas, introducing it 
into a liquid sample of GVs and applying a HyperCEST pulse sequence (Steps 64–92). This 
requires some specialized equipment, some of which has been described earlier in the 
context of xenon NMR and MRI applications. The working steps and the equipment setup in 
particular require people with skills in NMR/MRI and some experience in setting up 
custom-made electronic devices. The hyperpolarization system is available as a commercial 
unit (see Equipment section and Figure 5a-e) or can be built according to previous 
publications. In either case, the system should be capable of delivering hyperpolarized 129Xe 
under very stable, continuous flow conditions ,.
To achieve good Hyper-CEST performance with a particular GV type, it is necessary to 
optimize the saturation power and duration to match the exchange conditions for Xe 
between GVs and the surrounding media,. In addition, attention must be paid to GV integrity 
during the bubbling or inflow of xenon into the phantom, since both hydrostatic pressure and 
bubbles can cause irreversible GV collapse.
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MATERIALS:
REAGENTS:
• Anabaena flosaquae/Aphanizomenon flosaquae (Culture Collection of Algae and 
Protozoa, Scottish Marine Institute, cat. no. CCAP 1403/13F)
• Halobacterium sp. NRC-1 as brine inclusions (Carolina Biological Supply 
Company, cat. no. 154777) (OR) Halobaterium sp. plate (Carolina Biological 
Supply Company, cat. no. 154801)
• Rosetta™ 2(DE3) pLysS competent E. coli cells (EMD Millipore, cat. no.71401–
3)
• BL21 (DE3) competent E. coli cells (NEB, cat. no. C25271)
• Cyanobacteria BG-11 Freshwater solution 50x (Sigma, cat. no. C3061)
• Phosphate Buffered Saline without calcium and magnesium (PBS, Corning, cat. 
no. 21–040)
• Sodium Nitrate, High Purity Grade (NaNO3, Amresco, cat. no. 0598)
• Potassium Phosphate monobasic (KH2PO4, Sigma, cat. no. P5655)
• Magnesium Chloride hexahydrate (MgCl2.6H2O, Sigma, cat. no. M9272)
• Trisodium Citrate dihydrate (Sigma-Aldrich, cat. no. S1804)
• Potassium Chloride (KCl, Sigma, cat. no. 746436)
• Casein Hydrosylate (Sigma, cat. no. 22090)
• Yeast Extract (BD, cat. no. 212750)
• Magnesium sulfate heptahydrate (MgSO4.7H2O, Sigma, cat. no. 230391)
• Calcium Chloride dihydrate (CaCl2.2H2O, BDH Chemicals, cat. no. BDH9224)
• Sodium metasilicate nonahydrate (Na2SiO3.9H2O, Sigma, cat. no. S4392)
• Sodium Carbonate (Na2CO3, Sigma, cat. no. 71345)
• Sodium Bicarbonate (NaHCO3, Sigma, cat. no. S5761)
• Citric Acid, 1M (BDH Chemicals, cat. no. BDH7397)
• Ethylenediaminetetraacetic acid (EDTA), disodium salt dihydrate (Alfa Aesar, 
cat. no. A15161)
• Ferric Ammonium Citrate (Amresco, cat. no. 0846)
• Solulyse Bacterial Protein Extraction Reagent, in Tris.HCl Buffer, pH 7.4 
(Genlantis, cat. no. L200500)
• D-Sorbitol (Sigma, cat. no. S1876)
• Deionized (DI) water (tap supply)
• Anhydrous dimethyl sulfoxide (Life technologies, cat. no. D12345)
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• N-Hydroxy-Succinimidyl-Ester moiety such as Alexa-488-NHS (Thermo Fisher, 
cat. no. A20000)
• Tris-HCl buffer (Teknova, cat. no. T1080)
• HEPES (Sigma, cat. no. H3375)
• Terrific broth (Sigma, cat. no. T0918)
• Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Anatrace, cat. no. I1003)
• Kanamycin (Sigma-Aldrich, cat. no. K1377)
• 2% Uranyl Acetate (EMS, cat. no. 22400–2)
• Urea (VWR, cat. no. 0568)
• Sodium Hydroxide (NaOH, Sigma, cat. no. 221465)
• Sodium Chloride (NaCl, Sigma, cat. no. 793566)
• Sodium Phosphate Monobasic (NaH2PO4, Amresco, cat. no. 0823)
• 10X Tris/Glycine/SDS buffer (Bio-Rad, cat. no. 161–0732)
• Protein standard (Bio-Rad, cat. no. 161–0375)
• Laemmli sample buffer (Bio-Rad, cat. no. 161–0737)
• Gel electrophoresis power supply (Bio-Rad, cat. no. 164–5050)
• Gel electrophoresis cell (Bio-Rad, cat. no. 165–8004)
• Any kD SDS-polyacrylamide gels (Bio-Rad, cat. no. 456–9034)
• SimplyBlue™ SafeStain (Invitrogen, cat. no. LC6060)
• Bradford Reagent (Sigma-Aldrich, cat no. B6916–500)
• Pierce™ 660 nm protein assay reagent (Thermo-Fisher Scientific, cat. no. 22660)
• Bovine serum albumin (Thermo-Fisher Scientific, cat. no. 15561020)
• Ni-NTA Superflow Resin (Qiagen, cat. no. 30450)
• Poly-prep chromatography columns (Bio-Rad, cat. no. 7311550)
• Imidazole (Sigma, cat. no. 792527)
• 2-mercaptoethanol (Bio-Rad, cat. no. 1610710)
• DNaseI (NEB, cat. no. M0303S)
• Lysozyme (Sigma-Aldrich, cat. no. L6876)
• GvpCWT, ΔN&C-GvpC and GvpC-SpyTag genes in pET28a plasmid (Addgene, 
ID no. 85732, 85736 and 85737 respectively)
• SpyCatcher-mNeonGreen in pET26b plasmid (https://www.addgene.org/vector-
database/9135 )
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• pST39 plasmid containing pNL29 Mega GV gene cluster (Addgene ID no. 
91696)
• SOC Outgrowth Medium (NEB, cat. no. B90205)
• Luria-Bertani (LB) Broth base powder (Invitrogen™ by Life Technologies, cat. 
no.12795–084)
• Ampicillin (Sigma, cat. no. A0166–25G)
• Chloramphenicol (Sigma-Aldrich, cat. no. C0378)
• Glucose (Sigma-Aldrich, cat. no.G8270)
• Glycerol (Sigma-Aldrich, cat. no.G5516)
• Phosphate buffered saline (PBS), 20x solution (Teknova, cat. no. P1225)
• SCID Hairless Outbred (SHO) (OR) SCID Hairless Congenic (SHC) mice, 
female, 4–6 weeks of age (Charles River, cat. no. 474 (OR) 488)
!CAUTION All procedures involving animal use must be performed in 
accordance to institutional guidelines and regulations and approved by relevant 
Animal Care and Use Committees.
• Sterile PBS (Life Technologies, cat. no.10010–023)
• Isoflurane USP (Fresenius Kabi, cat. no.M60303)
• Medical air USP cylinder (Praxair)
!CAUTION Gaseous anesthesia must be scavenged properly using a charcoal 
canister or house vacuum to minimize potential exposure to humans.
• Charcoal canister (F-Air, Braintree, cat. no. F-AIR EA)
• Eye ointment (Lacri-Lube, Refresh) (OR) Lubricating gel (Aquagel, Parker, cat. 
no. 57–05)
• 0.9% Sodium Chloride Injection, (Baxter, cat. no. JB1322 (OR) VWR, cat. no. 
47729–565 )
• Ultrasound gel (WavelengthCL, National Therapy Production Inc., cat. no. 
NTPC500X) (OR)
• Aquasonic 100 ultrasound transmission gel (Parker Lab Inc. ,VWR, cat. no. 
68200–712)
• Electrode gel (Signa gel, Parker Lab Inc., cat. no. 15–25)
• Nair™ lotion (Church & Dwight co., Inc.)
• Vetbond tissue adhesive glue (Fisher Scientific, cat. no. NC9259532)
• SPHERO™ polystyrene particles, 4–5-4.9 μm (Spherotech, cat. no.PP-45–10)
• Agarose (Biorad, cat. no. 161–3102)
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• Xenon gas mixture: 2–5% (vol/vol) Xe (natural abundance with 26.4% (vol/vol) 
129Xe is sufficient), 10% (vol/vol) N2, He balance, grade 5.0 (Praxair))
▴CRITICAL The gas tank should have a pressure regulator for adjustments 
around 2 bar absolute pressure. The gas amount to be used depends on the flow 
rate through the system. A typical value would be 0.25 L/min, i.e. 15 L per hour.
EQUIPMENT:
• Shaker-Incubator with cooling, CO2 control and illumination (Infors HT, 
Multitron II) (Exact setup used is shown in Figure 2a-b)
• Benchtop centrifuge with swinging bucket rotor (Beckman Coulter, Allegra 
X-15R)
• Benchtop micro-centrifuge (Eppendorf 5424R)
• Barnstead™ GenPure™ xCAD Plus UV/UF Water Purification System (Thermo 
Scientific, cat. no. 50136146)
• Pyrex™ 500 mL and 1000 mL Erlenmeyer Flasks (Corning, cat. no.4980, 
stopper no. 9)
• Pyrex™ 500 mL Separatory Funnel (Cat. no.6402–500, stopper no. 24)
• Pyrex™ Culture Tubes (Corning, cat. no.9820)
• Pyrex™ 250 mL, 500 mL and 1 L media storage bottles (Corning, cat. no. 1395)
• 4L Beaker (Thermo Scientific Nalgene, cat. no. 1201–4000)
• 15 and 50 mL centrifuge/falcon tubes
• 1.5, 1.7 and 2 mL micro-centrifuge tubes
• Metal ring stand for separatory funnel
• Vacuum driven disposable bottle top filter (Durapore™,0.22 μm, Millpore, cat. 
no. SCGVT05RE)
• Adjustable volume pipets and pipet tips (100–1000 μL, 20–200 μL, 2–20 μL and 
0.5–2.5 μL, Eppendorf Research Plus)
• Serological pipets (1, 5, 10 mL and 25 mL, VWR)
• Syringes, Luer-lok tip, 1mL, 3mL, 10 mL and 30mL (BD, cat. no.309602, 
309657, 309604 and 309650)
• 18G and 1”/1.5” 21.5G flat bottom needles (SAI B18–100 and B21–150/B21–
100)
• Gel-loading pipet tips (Corning, cat. no. 4884)
• Regenerated cellulose dialysis tubing, 6–8kDa cutoff (Spectrapor, cat. no. 
1326650)
• Formvar/Carbon 200 mesh Cu TEM grids (Ted Pella Inc., cat. no. 01801)
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• Ultracentrifuge (Beckman-Coulter Avanti J-30I)
• Ultracentrifuge bottles (Beckman-Coulter)
• PD10 desalting columns (GE Healthcare Life Sciences, cat. no. GE17–0851-01)
• 1 cm path-length quartz cuvette (Hellma Analytics, cat. no. 176.700-QS)
• Pressure controller (Alicat Scientific, cat. no. 73907)
• UV-Vis Spectrophotometer (Ocean Optics Inc., STS series microspectrometer, 
350–800 nm, 50 μm slit, 400 core/1cm SMA input, cat. no. STS-VIS-L-50–400-
SMA) equipped with a 400 μm fiber in the VIS/NIR range (2m, cat. no. P400–2-
VIS-NIR) and a Krypton lightsource (2000 hour bulb, ECOVIS) and 
accompanying Oceanview spectroscopy software.
• Compressed Nitrogen cylinder with pressure regulator (Air Liquide)
!CAUTION Proper safety techniques should be followed when opening and 
handling the compressed gas cylinder. Make sure the cylinder is secured to a wall 
and properly connected to pressure regulator before opening.
• ZetaPALS dynamic light scattering instrument (Brookhaven Instruments)
• Disposable cuvette (Eppendorf, cat. no. Z605050)
• Plate-reader spectrophotometer (Molecular Devices SpectraMax M5)
• Gel imaging system (BioRad Chemidoc MP, model no. 170–8280)
• Water bath (various sources, e.g. Fisher Scientific, cat. no.15–462-6Q)
• Disposable culture tube, 16 × 100mm (VWR, cat. no. 47729–576)
• Dialysis clips, weighted/unweighted closures, 55 mm sealing width (Spectrum 
Labs Inc., cat. no. 132745/132737)
• Transmission electron microscope (FEI Tecnai T12 LaB6 120 kV) equipped with 
a Gatan Ultrascan 2k X 2k CCD and Leginon automated data collection software 
suite
• Glow Discharging System (Emitek K100X)
• PELCO reverse, anti-capillary tweezers (TedPella, 5378-NM)
• Glass slides (VWR Microslides, cat. no. 48382–171)
• Filter paper (Whatman™, cat. no. 1001–090)
• Pipet-Aid (Drummond Scientific Co.)
• Magnetic Stirring Bars (VWR)
• Rotatory Shaker (Rotamix, Appropriate Technical Resources, model RKVS)
• Microvolume Spectrophotometer (NanoDrop™ 2000C series, Thermo Scientific, 
cat. no. ND-2000C)
• Tail vein catheter (SAI Infusion Technologies, cat. no. BF-27–01)
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• Syringe with tip cap, 12 mL (Luer Lock Kendall Monoject, cat. no.1181200777)
• Needle, 27G x 1/2 (PrecisionGlide, BD, cat. no. 305109)
• Tuberculin Syringe, 1/2cc (BD, cat. no. 305620)
• Surgical tape (Transpore, 3M, cat. no. 1527–1)
• Alcohol wipes (Webcol, Covidien, cat. no. 63001) (OR) (BD, cat. no. 
BD326895)
• Cotton swabs
• Syringe pump (New Era Pump System, cat. no. NE-1000 (OR) Kent Scientific 
Corporation, model. GenieTouch) (Typical setup shown in Figure 4b).
• Heatlamp (Home Hardware)
• Ultrasound imaging system (Vevo®2100, VisualSonics, Fujifilm (OR) 
Verasonics Vantage 256™, Verasonics. Inc.) (Typical setup shown in Figure 4a-
d).
• Ultrasound transducer (L11–4v Verasonics Inc., (OR) L22–14v Verasonics, Inc., 
(OR) MS250, VisualSonics, Fujifilm)
• Acoustic absorber sheet, 300mm x 300 mm (Precision Acoustics Ltd., cat. no. 
F28-SMALL)
• Multi-well phantom mold (3-D printed)
• Plastic reservoir for phantom preparation (Nalgene™ flat-bottom polypropylene 
robotic reservoirs , cat. no. 1200–1300)
• Computer-controlled translation stage (X-Slide, Velmex, Inc.).
• MATLAB (Licensed Software, Mathworks, Inc.)
• Animal heat pad (Braintree Scientific, Inc. cat. no. HP 1M)
• Temperature controller (Braintree Scientific, Inc. cat. no. TCAT 2DF)
• Rectal probe for mice (Braintree Scientific, Inc. cat. no. RET 3)
• Vevo® Imaging Station (VisualSonics, Fujifilm)
• PE10 plastic tubing (Becton Dickinson, cat. no. 427400)
• 30G needles (Becton Dickinson, cat. no. 305106)
• Rodent anesthesia machine (Patterson Veterinary, cat. no. 07–870-3592 (OR) 
VetEquip, cat. no. 901806)
• Weighing Balance (sensitive in the g and mg range)
• MR imaging system (Bruker); preferably a vertical NMR spectrometer at field 
strength of 7 T or higher with micro-imaging capability for 1H and 129Xe; a 
variable temperature unit (VTU) is desirable to keep the sample temperature 
stable either at room temperature or at physiological body temperature.
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▴CRITICAL The operating console needs at least one available trigger signal 
output (TTL) to be connected to a photoMOS relay for regulating the gas flow
• Dual-tuned 1H/129Xe NMR coil with 10 mm inner diameter (Bruker)
• Non-selective NMR pulse sequence for acquiring a direct Xe NMR spectrum 
after fresh Xe delivery. This is implemented by using a simple (pulse – acquire) 
sequence; the sequence starts with two trigger signals to communicate with the 
gas delivery manifold and then a block excitation pulse of adjustable amplitude, 
followed by an FID acquisition
• Multi-echo acquisition MRI pulse sequence (echo planar imaging [EPI] or rapid 
acquisition with relaxation enhancement [RARE], Bruker) with activatable 
magnetization transfer module (alternative: fat suppression or saturation transfer 
module) and two triggers.
• Hyperpolarization system for producing spin-hyperpolarized 129Xe(commercial 
systems are available through www.xemed.com, www.polarean.com or as an 
open source design)
! CAUTION The hyperpolarization system contains ~1 g of a highly reactive 
alkali metal such as Rb. Make sure to be familiar with the procedures for 
handling the system as provided by the manufacturer
▴CRITICAL The system must be capable of producing hyperpolarized Xe in 
continuous flow mode for repeated re-delivery into the sample solution.
• Gas flow controller with a maximum flow rate of100 standard mL/min (SMLM) 
(Omega Engineering Inc., model no. FMA 5408) and second one of 500 SMLM 
flow (Omega Engineering Inc., model FMA5412)
▴CRITICAL Such gas flow controllers are typically calibrated for N2 gas; the 
correction factors for systems based on heat flux measurements applied to the Xe 
gas mix are: 1.44 for the Xe fraction, 1.454 for the He fraction. Hence the 
correction factor for a 5% Xe mix is 0.05×1.44 + 0.1×1 + 0.85×1.454 = 1.408.
• Pressure controller for up to 6 bar and 1 standard liter per minute flow 
(Bronkhorst, model no. P-702CV-6K0A-AAD-22-V)
• Direct solenoid actuated poppet “shortcut” valve (Norgren, model no. 9502310,)
• PhotoMOS relay (Panasonic, model no. AQY210EH,)
• PC-operated control interface for the hyperpolarization system and the gas flow 
controllers based on a data acquisition board (Daq/Board3000, Omega 
Engineering Inc.) and a graphic user interface (e.g., DASYLab or LabView, 
National Instruments)
• Glass phantom (made from thick wall NMR tube of 10 mm outer diameter, 
Wilmad) with inlet and outlet adapter with size 7 chem threads (pieces CG-350–
01 from ChemGlass Life Sciences), see Figure 5a
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• 5 mm standard NMR tube to be inserted into the glass phantom to create a 
second compartment inside the 10 mm NMR tube
• ¼ inch PFA flexible tubing (Swagelok)
▴CRITICAL Ensure that the PFA tubing directing the Xe flow from the 
hyperpolarizer into the sample does not go through any zero-field crossings in 
the fringe field of the superconducting magnet because this might cause loss of 
hyperpolarization.
• Fused silica glass capillaries for Xe dispersion (e.g five pieces of ca. 15 cm 
length each and 350 μm outer diameter, e.g. material no. 106815–0030, 
Polymicro)
• Glass connecting tube with size 7 chem threads on either end (Figure 5b)
• Home-made capillary holder; ca. 40 mm long, on the inlet side a 20 mm deep, 
5mm diameter bore, on the outlet side 5 clear bores matching the outer diameter 
of the capillaries (like in Figure 5c; Teflon or Delrin material)
• pH meter
• Magnetic Stir Plate (Thermo Scientific, cat. no. S194925)
• Autoclave
• Bunsen Burner
• Spark Lighter
REAGENT SETUP:
G625 growth medium for Anabaena flos-aquae (Ana) (4 L): 5.84 mM NaNO3, 224 
μM KH2PO4, 304 μM MgSO4.7H2O, 208 μM Na2SiO3.9H2O, 189 μM Na2CO3, 10 mM 
NaHCO3, 245 μM CaCl2, 31 μM citric acid and 3 μM EDTA. Separately, add 24 mg of ferric 
ammonium citrate to 1 mL of ultrapure water (in a 1.5 mL micro-centrifuge tube). Heat in a 
42°C water-bath for 10–15 min to dissolve before adding to the media in the Nalgene 4L 
beaker. Adjust to pH 8.0 with HCl. Filter sterilize using a 0.22 μm bottle-top filter. G625 
growth media prepared using this method is stable for at least 6 months if stored in a cool, 
dry place at room temperature under sterile conditions. Since the iron sediments, make sure 
that the bottle is swirled each time before use.
Carolina growth medium for Halobacteria salinarum-NRC1 (Halo) (1 L): 4.278 M 
NaCl, 81 mM MgSO4.7H2O, 10 mM Trisodium citrate dihydrate, 27 mM KCl, 5g/L casein 
hydrolysate and 3g/L yeast extract. Adjust pH to 7.2 with NaOH and autoclave at 121˚C and 
18 psi for 30 minutes. Autoclaved media can be stored for at least 6 months under sterile 
conditions at room temperature.
TMC lysis buffer for Halo GVs: 10 mM Tris-HCl, 2.5 mM MgCl2 and 2mM CaCl2, pH 
7.5. Store indefinitely.
Sorbitol lysis buffer for Ana GVs: 1M D-Sorbitol in distilled water. Store indefinitely.
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Terrific Broth (TB): Add 47.6 g of TB powder and 8 mL glycerol to 1L of distilled water. 
Autoclave at 121°C for 15 m. Autoclaved media can be stored for at least 6 months under 
sterile conditions at room temperature.
Luria-Bertani (LB) Broth: Add 25 g of LB powder to 1 L of distilled water. Autoclave at 
121°C for 15 m. Autoclaved media can be stored for at least 6 months under sterile 
conditions at room temperature.
Kanamycin stock solution: 50 mg/mL in distilled water.
Ampicillin stock solution: 100 mg/mL in distilled water.
Chloramphenicol stock solution: 25 mg/mL in ethanol.
IPTG inducer stock solution: 1M IPTG in distilled water.
GV stripping buffer (Round 1): 10M urea, 100mM Tris-HCl, pH 8.0–8.5.
GV stripping buffer (Round 2): 6M urea, 60mM Tris-HCl, pH 8.0–8.5.
TGS buffer: 1:9 (v/v) dilution of 10X TGS stock in DI H2O.
Inclusion body solubilization buffer: 6M urea, 20mM Tris-HCl, 500mM NaCl, pH 
8.0.
Inclusion body wash buffer: 6M urea, 20mM Tris-HCl, 500mM NaCl, 20mM 
imidazole, pH 8.0.
Inclusion body elution buffer: 6M urea, 20mM Tris-HCl, 500mM NaCl, 250mM 
imidazole, pH 8.0.
Soluble protein wash buffer: 50mM NaH2PO4, 300mM NaCl, 20mM imidazole, 1mM 
2-mercaptoethanol, pH 8.0.
Soluble protein elution buffer: 50mM NaH2PO4, 300mM NaCl, 250mM imidazole, pH 
8.0.
▴CRITICAL Antibiotic stocks and IPTG solution are at 1000x concentration and should be 
filter-sterilized after preparation and stored at −20°C. IPTG is light-sensitive and should be 
stored in the dark at −20°C. Lysis buffers and stock solutions for media preparation should 
be filtered (0.22 μm filter) and stored at room temperature. All protein purification buffers 
(wash and elution buffers) should be filter-sterilized and stored at 4°C.It is not advisable to 
use urea buffers more than a week old for protein purification. GV stripping buffers should 
be freshly prepared before each use.
Ultrasound gel preparation for imaging experiments: Take a 30 mL luer-lok 
syringe, remove the piston and place the syringe with the tip facing down in a 50 mL falcon 
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tube. Fill the syringe with ultrasound gel before loading the falcon tube into a table top 
centrifuge. Spin at 2500g for 30 minutes to ensure that there are no air bubbles in the gel and 
keep at room temperature. It is advisable to prepare the gel on the same day of the 
experiment, as longer storage may lead to drying if the syringe is not sealed tightly.
EQUIPMENT SETUP:
Cleaning and sterilization of glassware: Clean and sterilize all glassware by 
autoclaving and fully dry them before use.
Setting up the apparatus for pressurized absorbance spectroscopy: The setup 
used to conduct pressurized absorbance spectroscopy is illustrated in Figure 3 and includes 
the following components: (i) computer equipped with MATLAB to run the collapse 
pressure scripts, (ii) compressed N2 tank with control valves and a regulator, (iii) pressure 
controller, (iv) flow-through quartz cuvette, (v) UV-Vis spectrometer equipped with a light 
source and cuvette holder.
Couple the pressure controller to the gas tank via a stainless steel gas connector, to the 
computer via a USB port, and to the flow-through cuvette via plastic cannulae. Connect the 
Ecovis Krypton light source of the UV-Vis spectrometer to a power supply, allowing light to 
pass through the sample in the quartz cuvette. The transmitted light then passes through an 
optical fiber connector into the OceanOptics STS microspectrometer. The spectrometer is 
connected to the computer and controlled by a MATLAB script, which also interfaces with 
the pressure controller. These scripts can be downloaded from http://shapirolab.caltech.edu/?
page_id=525. An equilibration time of 7 seconds at each pressure step and a final collapse 
pressure of 1400 kPa (for blanking) is hard-coded into the script and kept constant for all 
measurements. Before acquiring sample measurements, the system is calibrated by 
recording the spectra for full transmission (using the cuvette loaded with PBS or buffer of 
choice) and zero transmission (by turning the cuvette 90° so that no light passes through).
!CAUTION Ensure that the compressed nitrogen tank is transported and stored safely. 
Cylinders should be secured and stored upright in a cool dry area protected from 
combustible materials. The gas valve seal must always be in place. When not in use, keep all 
the cylinder and regulator valves shut and the pressure controller and spectrometer powered 
off.
Setting up the Verasonics imaging station and imaging parameters: The 
Verasonics imaging system and setup for in vitro and in vivo experiments is shown in Figure 
4a-b and comprises the following components: (i) computer, (ii) ultrasound probe, (iii) 
translatable probe clamp equipped with three independent motors that move in the x, y and z 
directions with μm-level precision (iv) fixed phantom holder and (v) Verasonics scripts 
running on MATLAB software. Adapt the setup for in vivo imaging by replacing the 
phantom holder with a mouse mounting platform equipped with a heating pad, anesthesia 
equipment and nose-cone for the animal and a manually translatable probe clamp.
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CRITICAL Make sure that the probe is well coupled to the sample and that the transducer 
array of the probe is immersed in liquid or covered with ultrasound gel before transmitting 
ultrasound.
GVs can be imaged using the Ray-lines Verasonics example script. Imaging is typically 
performed at around 18 MHz using the L22–14v transducer with an F-number of 2 or 3, 
focal depth of 8 mm (matching the natural focus of the transducer) and 6 cycle pulses. For 
these parameters, nondestructive imaging of GVs can be performed at voltages of or below 
3V. The onset of GV collapse usually takes place at around 5V. For efficient GV destruction, 
a 25V pulse is applied for a few seconds.
GVs are imaged at lower frequencies around 6.25 MHz using the L11–4v transducer and the 
corresponding Ray-lines script. The F-number is set to 2, transmit focus to 20 mm and 
transmit voltage to 1.6V. Images are saved from the Verasonics graphical user interface.
Setting up the Vevo imaging station and imaging parameters: The imaging 
station setup is depicted in Figure 4c-d, and encompasses the following components: (i) 
bench-top rail system; (ii) 3D stepper motor; (iii) ultrasound probe clamp; (iv) mouse 
handling table; and (v) physiological monitoring unit. Make sure that the 3D motor is 
connected to the Vevo®2100 ultrasound system to allow for 3D image acquisition. Also 
connect the physiological monitoring unit to the Vevo®2100 system to allow on screen 
tracking of physiological parameters, such as heart rate, respiratory rate and body 
temperature.
Halo gas vesicles are imaged under the following imaging settings using the Vevo®2100 
system: (i) frequency - 21MHz and 18MHz for B-mode and contrast mode respectively; (ii) 
transmit power - 2%; and (iii) gain - 16dB and 32dB for B-mode and contrast mode 
respectively. The imaging field of view can be adjusted accordingly to fit the tissue region of 
interest, by increasing or decreasing the image width and depth.
▴CRITICAL It is crucial to keep the transmit power on the Vevo®2100 system to 2%, to 
allow for stable imaging of Halo gas vesicles. Higher transmit power will collapse exposed 
GVs.
Setting up the syringe pump: Gas vesicle injections are administered as a bolus using a 
syringe pump (shown in Figure 4b). The following settings are used for each injection: (i) 
syringe diameter - 3.55 mm (inner diameter of a BD 1/2cc Tuberculin Syringe); (ii) injection 
rate - 300 μL/min to 500 μL/min; and (iii) injection volume – 50 μL.
Installing the control electronics for the 129Xe MRI: Set up the TTL output of the 
spectrometer with the photoMOS relay such that the latter one controls the status of the 
shortcut valve (see Figure 5d for the circuit). This is used to alternatingly force gas flow 
through the sample or to bypass the sample. From the Daq/board, use one analog output to 
operate the set points of the flow and pressure controllers. Connect one analog input each to 
read the process values of the controllers. Display the corresponding parameters through 
appropriate elements in the DASYLab/LabView software.
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Preparation of the Xe gas delivery manifold: The timing of Xe bubbling is controlled 
by the pulse sequence and achieved through a proper gas delivery system by connecting the 
PFA tubing and controllers according to Figure 5e. Prior to each experiment, insert the (five) 
capillaries into the capillary holder. The end tips should reach close to the bottom of the 
glass phantom.
▴CRITICAL This design of the flow and pressure controllers prevents Xe gas from passing 
through any needle valves or (electro-) magnetic units during its transfer from the 
hyperpolarizer to the sample, thus minimizing the depolarization of Xe.
▴CRITICAL Gas bubbles can cause serious image artifacts if persistent during image 
acquisition. Therefore, the bubbling has to be stopped and the sample has to settle down 
prior to acquisition. Fresh hyperpolarized xenon has to be re-delivered for each subsequent 
acquisition.
MRI pulse sequence setup: The non-selective NMR sequence for acquiring direct Xe 
NMR spectra is adapted from an existing simple FID sequence by implementing the TTL 
trigger pulses and bubble/wait delays prior to the 90° block pulse (Figure 5e). The FID 
sampling window is typically 1000 ms and the spectral width to cover is ca. 350 ppm. For 
Xe MRI imaging sequence, single-shot pulse sequences should be used to make the most 
efficient use of the non-renewable Xe polarization. A single-shot EPI pulse sequence can be 
used when long T2* values are expected. Alternatively, a single-shot RARE pulse sequence 
can be used and is limited by T2. To set up the imaging sequence, take a standard sequence 
with image encoding of your choice (EPI or RARE) and implement a magnetization transfer 
or saturation module (Bruker ParaVision terminology) after the TTL trigger pulse for xenon 
delivery and prior to the k-space encoding. The saturation offsets are defined through a 
saturation frequency list. This list can be accessed by providing in the ParaVision graphical 
user interface a menu to enter a fixed number of saturation pulse frequency offsets. Point 
these entries to the saturation frequency list. Finally, loop the entire xenon delivery, wait 
time, the saturation pulse and the imaging sequence multiple times to walk through the 
entire saturation frequency list. Some general parameters when implementing the sequence 
are: a field-of-view of 20 × 20 mm2; matrix size 32 × 32 (in-plane spatial resolution: 625 
μm2); slice thickness: 20 mm; repetition time including saturation time and xenon delivery: 
ca. 18 s.
Detailed parameters for RARE sequence: 90° Hermite excitation pulse: length = 3.375 ms, 
bandwidth = 1,600 Hz; 180° Mao refocusing pulse: length = 3.105 ms, bandwidth = 2,000 
Hz; short echo time of ca. 10 ms (this is also the effective echo time as centric encoding is 
used here), echo readout time of 2.66 ms; ensure the RARE factor is set to give a single-shot 
acquisition, i.e., a RARE factor of 32 is used when the image matrix size is 32.
Detailed parameters for EPI sequence: 90° Gaussian-shaped excitation pulse: length = 1.0 
ms, bandwidth = 2,740 Hz; encoding: partial Fourier-acceleration factor = 1.68 (i.e. 19 out 
of 32 k-space lines) and double sampling; short echo time of ca. 6 ms; echo train readout 
time of 6.01 ms for 19 k-space lines.
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PROCEDURE:
Production and purification of gas vesicles (GVs): 1| Gas vesicles can be produced 
natively in cyanobacterial (Ana GVs) or haloarchaeal (Halo GVs) hosts. In addition, they 
can be heterologously expressed in E. coli (Mega GVs). To produce and purify Ana, Halo or 
Mega GVs, follow steps in Option A, B, or C respectively.
(A) Producing and purifying Ana GVs ● TIMING 4.5 weeks
(i) Making Ana starter cultures (Steps i-iv: ● TIMING 2 wks) Open the seal of 
the primary culture tube of Anabaena flosaquae (as received from CCAP, UK), 
and loosen the screw cap to allow aeration of the culture. Let the tube stand 
upright and undisturbed for 2 days in a cool (room temperature i.e. (18–25 °C)), 
dry place with access to ambient light. Viable Ana cells producing GVs will 
float to the top of the tube, forming a dark green layer.
(ii) Take a pre-sterilized Pyrex glass culture tube. Aliquot 9 mL of G625 growth 
media into the tube in the presence of a flame to ensure sterility. Add 0.2 mL of 
50x BG-11 cyanobacteria freshwater solution. Swirl a few times to ensure 
complete mixing.
(iii) Gently transfer 0.8 mL of the floating green cells from the primary culture to the 
G625 media in the culture tube to make a total volume of 10 mL. Swirl gently to 
disperse the cells. The culture should have just a hint of green at this stage.
(iv) Transfer the starter culture to the shaker incubator (shown in Figure 2b) and 
allow it to grow at 25°C, 100 rpm and 1% CO2 with cycles of 14 hours of light 
illumination and 10 hours in the dark until the cells form a dense, floating green 
layer that is clearly visible at the top of the liquid phase. This growth typically 
takes around 1–2 weeks. Note that the doubling time of Anabaena flosaquae 
during exponential phase is ~ 56.5 hours, so depending on the number of viable 
cells in the starter culture, it will take 1–2 weeks to produce enough floating 
green cells that have the ability to produce GVs. Viable cells typically form the 
dense layer at the top and dead cells sink to the bottom of the tube.
?TROUBLESHOOTING
(v) Sub-culturing Ana for GV production (Steps v-vi: ● TIMING 2 wk) 
Aliquot 200–250 mL of G625 media into an autoclaved 1L Erlenmeyer flask 
(use a bunsen burner flame or a laminar hood to provide a sterile environment to 
avoid contamination). Add 1x final concentration of BG-11 freshwater solution 
(4–5 mL of the 50x stock) just before inoculation with Ana starter culture. Swirl 
to mix components.
(vi) Inoculate 2 mL of the green, floating layer of the starter culture per flask and 
grow cells in the incubator at 25°C, 100 rpm, 1% CO2, 14 h light and 10 h dark 
cycle until they become confluent (as shown in Figure 2b-c). This should take ~ 
2 weeks, with the exact time depending on the number of viable cells inoculated.
?TROUBLESHOOTING
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(vii) Harvesting Ana GVs (Steps vii-xi: ● TIMING 1 d) Pour the confluent 
culture from the flask into a separatory funnel (pre-sterilized with stopcork in 
place), allowing it to stand undisturbed on a metal ring stand for 12–16 hours 
until the GV-producing Ana cells separate from the spent media to form a 
compact green layer at the top (Figure 2e).
(viii) Carefully remove most of the spent media by opening the stopcork at the bottom 
of the funnel and retain only the green fraction at the top along with ~30 ml of 
media.
(ix) Using a 25 mL serological pipet, gently resuspend the cells and transfer to a 50 
mL tube.
(x) Use 10 mL of fresh G625 growth media to collect cells sticking to the walls of 
the funnel. Each flask should be reconstituted to ~ 50 mL of concentrated cell 
suspension.
(xi) plit the suspension into two falcon tubes and add equal volume of 1M sorbitol 
(final concentration is 500 mM) and 10% (vol/vol) of Solulyse (i.e. 5.5 mL in 55 
mL) to achieve hypertonic lysis. Place the tubes in a rotatory shaker at 4°C for 
6–8 hours. Green lysates will have a milky tinge post-lysis due to the presence 
of GVs.
CRITICAL STEP We have observed that GVs become structurally 
compromised by certain detergents and surfactants used routinely for cell lysis 
such as BugBuster (EMD Millipore), Triton-X and sodium dodecyl sulfate. It is 
therefore advisable to thoroughly characterize the effect of any new detergent on 
GV structure and integrity using techniques such as TEM and pressure 
absorbance spectroscopy before using them for ultrasound and MRI.
?TROUBLESHOOTING
(xii) Isolation and purification of Ana GVs from lysate (Steps xii-xvii: ● 
TIMING 2–3 d) Transfer 35 mL of cell lysate to a 50 mL tube and centrifuge at 
350g, 8°C for ~24 hours in a table-top centrifuge, preferably equipped with a 
swinging bucket rotor.
?TROUBLESHOOTING
(xiii) Slowly remove as much as possible of the green subnatant liquid and cell pellet 
using a 25 mL serological pipet, without disturbing the white GV layer on top.
(xiv) For the second and third round of centrifugation (350g, 8°C), resuspend the 
white supernatant layer containing GVs in 25 mL of sterile 1x PBS (Corning). 
During each resuspension step, gently wash the inner walls of the falcon tube 
with fresh PBS to recover GVs sticking to the sides. The green subnatant should 
progressively become clearer with each spin. The second and third rounds of 
centrifugation are shorter than the first, with the endpoint being when all the 
GVs rise to the top of the tube.
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(xv) For the final spin, resuspend GVs in 10–12 mL of PBS (total volume can be 
varied depending on GV yield) and aliquot them into 2 mL tubes. Spin in a 
microcentrifuge at 350g for 4 hrs at 4–8°C.
CRITICAL STEP Do not fill the tube to the brim as GVs will get stuck to the 
lid of the tube when they float to the top during centrifugation
?TROUBLESHOOTING
(xvi) Using a 21.5 G flat needle attached to a 3 mL syringe, maintain the angle of the 
microcentrifuge tube and slowly insert the needle through the GV film to the 
bottom. Collect most of the subnatant and slowly take out the needle. Some GV 
loss will occur at this step. This is OK as long as most of the GVs do not get 
sucked up into the syringe.
(xvii) Resuspend the purified GVs in ~ 6–8 mL of PBS (exact volume of added PBS 
can be varied and is determined by how concentrated the GV solution needs to 
be for the end application) and aliquot the milky white GV solution (Figure 2j) 
into screw-top vials or microcentrifuge tubes.
▪ PAUSE POINT The Ana GVs aliquoted into tubes can be stored for up to a year at 4°C.
CRITICAL STEP Avoid freezing and subjecting the tube to shocks, such as dropping to 
the ground or snapping the cap, as this may collapse the GVs.
(B) Producing and purifying Halo GVs ● TIMING 3.5 weeks
(i) Growing Halo cultures for GV production (Steps i-iii: ● TIMING 2 wks) 
Aliquot 250 mL of Carolina growth medium in to an autoclaved 1L Erlenmeyer 
flask under sterile conditions.
(ii) Inoculate Halo cultures using one of the following methods. (1) Using a sterile 
pipette tip or toothpick, scrape a small amount of pink culture from the agar 
plate to add to the flask as inoculum. (2) Use one to two brine crystals 
containing Halo for inoculation. (3) Inoculate 2.5 mL from a healthy pink liquid 
starter culture into 250 mL of fresh growth medium (1:100).
(iii) Grow the culture in an incubator at 42˚C with 100 rpm shaking. Depending on 
the health of the parent culture, it may take ~ 2 weeks for the inoculated culture 
to become confluent . Confluency is determined by the color and turbidity of 
cultures as shown in Figure 2d.
?TROUBLESHOOTING
(iv) Harvesting Halo GVs (Steps iv-vi: ● TIMING 1 wk) Gently pour the culture 
from the flask into a separatory funnel (pre-sterilized with stopcork in place). 
Allow the culture to remain undisturbed until a visible ring is formed at the top 
(Figure 2f). This typically takes 4–6 days.
(v) Remove as much of the spent media as possible by opening the stopcork, 
retaining only the buoyant layer of milky-pink cells for lysis. The retained 
volume is~10–20 mL , and a lot of cells stick to the sides of the funnel.
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(vi) Using equal volume (10–20 mL) of TMC lysis buffer (pH 7.5), gently wash the 
cells stuck on the sides of the funnel and retrieve as many cells as possible. The 
volume of TMC buffer used might be varied depending on the cell density to 
achieve efficient hypo-osmotic lysis. However, note that if too much buffer is 
used in this step, the number of 2 mL aliquots will proportionately increase for 
the next step, thus increasing sample processing time.
?TROUBLESHOOTING
(vii) Isolation and purification of Halo GVs from lysate (Steps vii-xi: ● 
TIMING 2 d) Aliquot ~1.6 mL of cells in 2 mL tubes and spin in a 
microcentrifuge at 300g for 4 hours at 8˚C.
▴CRITICAL STEP Close the tubes gently; the pressure wave caused from 
snapping the lid will collapse a large number of Halo GVs.
?TROUBLESHOOTING
(viii) At the top of the tube, a mixed layer of Halo GVs (white) and unlysed Halo cells 
(milky-pink) will be visible. Using a blunt end 18.5 or 21.5G needle, aspirate the 
pellet at the bottom of the tubes as well as the pink cell lysate. CRITICAL 
STEP Take care to limit the amount of floating Halo cells and Halo GVs (white) 
that are aspirated in to the syringe.
(ix) Transfer the GVs and unlysed Halo cells to fresh tubes and bring to 1.6 mL with 
1x PBS. Centrifuge tubes at 300 g for 4 hours at 8˚C.
(x) Repeat steps viii and ix. After each step, the amount of milky-pink buoyant cells 
will reduce and white Halo GVs will increase. Continue with centrifugally-
assisted floatation until all the cells have lysed and there is no evidence of pink 
cell lysate in the subnatant.
(xi) Resuspend the purified GVs in PBS and aliquot the milky white GV solution 
(Figure 2j) into screw top vials or microcentrifuge tubes.
▪ PAUSE POINT The aliquoted Halo GVs can be stored for up to one year at 4°C.
CRITICAL STEP Avoid freezing and subjecting the tube to mechanical shocks, such as 
dropping to the ground or snapping the cap, as this may collapse the GVs.
(C) Producing and purifying Mega GVs ● TIMING 4 d
(i) Heterologous expression of Mega GVs in E. coli (Steps i-iv: ● TIMING 2 d) 
Transform 50 μL chemically competent Rosetta™ 2(DE3) pLysS cells using > 1 
ng of pST39 plasmid containing the pNL29 Mega GV gene cluster by mixing 
the two components in a 1.5 mL tube and incubating on ice for 30 minutes. Heat 
shock the tube in a 42 °C water bath for 45 seconds, and put the tube back on ice 
for a minute. Add 500μL of SOC outgrowth medium and incubate in a shaker at 
37°C and 250 rpm for 1 hour.
(ii) Prepare 3 mL of LB broth containing 1x Ampicillin (100 μg/mL), 1x 
Chloramphenicol (25 μg/mL) and 1% (wt/vol) glucose in a glass culture tube. 
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Resuspend 300 μL of the transformed E. coli in the broth. Grow the culture in a 
shaker-incubator at 37°C and 250 rpm until OD600 reaches 0.4 – 0.6. Make 100 
μL aliquots of the culture in sterile tubes, and mix with 100 μL of 50% sterile 
glycerol. Freeze the tubes at −80°C as E. coli glycerol stocks.
▪ PAUSE POINT The glycerol stocks can be stored at –80°C and used for up to 
3 months. Note that while using glycerol stocks is convenient, the GV yield is 
reduced when using frozen stocks, so we recommend fresh overnight 
transformations for best results.
(iii) Resuspend a tube of the aliquoted glycerol stock in 3 mL LB broth containing 
1x Ampicillin, 1x Chloramphenicol and 1% (wt/vol) glucose. Grow the E. coli 
culture to saturation (OD600 > 4). For fresh transformations, aliquot 500 uL of 
the transformed E.Coli from Step (i) into 5 mL of LB broth containing 1x 
Ampicillin, 1x Chloramphenicol and 1% (wt/vol) glucose. Allow it to grow 
overnight until the culture reaches saturation (~ 16 hours).
(iv) Prepare 100 mL LB broth containing 1x Ampicillin, 1x Chloramphenicol and 
0.2% (wt/vol) glucose, and inoculate 1 mL of the saturated E. coli culture into 
the broth. Grow at 37°C for ~ 2 hours until OD600 reaches 0.4 to 0.6. Induce the 
culture by adding 20 μM IPTG (final concentration), and grow at 30°C for an 
additional 16–24 hours.
(v) Harvesting and purifying Mega GVs from E. coli cultures (Steps v-x: ● 
TIMING 2 d) Split the culture equally into three 50 ml Falcon tubes and spin 
for 1 hour at 500g and 25°C.
CRITICAL STEP Avoid higher speeds because they may cause collapse of 
GVs.
? TROUBLESHOOTING
(vi) Insert a 10mL syringe with needle to > 1 cm below the surface of the solution 
and withdraw the clear liquid component of the solution. Withdraw the liquid 
slowly to preserve the thin layer of cells floating at the top of the solution, as 
well as the pellet at the bottom, both of which contain Mega GVs.
(vii) To lyse the cells, add 4 ml SoluLyse-Tris reagent per 50 ml of E. coli culture, 
250 μg/ml lysozyme and 10 μg/ml DNAseI. Rotate the tubes for 10 minutes at 
room temperature and then aliquot 1.5 mL of the solution to 2 mL tubes. Spin 
samples for 4 hours at 800 g and 8°C. Mix the floating GV layer gently with 
supernatant and transfer to a clean tube.
(viii) Spin the samples for 4 h at 800g. Use a 3 mL syringe to remove the bottom 
fraction, which sometimes includes a small pellet. Gently resuspend GVs in 1 
mL of PBS. Repeat the spin and wash steps 3 times.
CRITICAL STEP Be aware that GVs are susceptible to desiccation and 
resuspend GVs immediately after withdrawing the liquid.
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(ix) Mega GVs are natively clustered. To uncluster them, GV-containing solution is 
mixed with 10 M urea in a 2:3 ratio to achieve 6 M final urea concentration, and 
the resulting solution is gently rotated for 30 min.
(x) Dialyze GVs overnight in 6–8 kDa MWCO tubing against 4L of PBS. This step 
can be omitted for experiments with no stringent requirements for buffer 
conditions. The white layer of unclustered GVs at the top of the liquid phase 
after buoyancy purification, as well as the re-suspended milky-white solution of 
Mega GVs in PBS is shown in Figure 2i-j.
▪ PAUSE POINT Mega GVs can be stored for up to one year at 4°C .
CRITICAL STEP Avoid freezing and subjecting the tube to mechanical shocks, such as 
dropping to the ground or snapping the cap, as this may collapse the GVs.
Quantification of GVs by measuring pressure-sensitive optical density ● TIMING 15 m: 
2| Determine the concentration of a solution of gas vesicles by measuring its pressure-
sensitive optical density at 500 nm (OD500,ps) using a NanoDrop 2000 Spectrophotometer. 
Load 2 μL of sample on the pedestal for each measurement. Collapsed gas vesicles in the 
same buffer are used as a blank for measurements. Prepare collapsed GVs by sonication in a 
water bath until the solution turns completely clear or by manual collapse in a capped 
syringe. For manual collapse, remove the plunger from a 12 mL Luer-Lock syringe closed 
with a tip cap and place 5–10 μL of gas vesicle solution at the bottom of the syringe. Making 
sure that the tip cap is screwed on tight, replace the plunger and push down until there is 
significant resistance. The increase in pressure will collapse the gas vesicles, turning the 
milky white solution clear. A shortcut for quick measurements of GV concentration is to 
blank with the GV resuspension buffer. For most samples, this will give an OD reading that 
is very close to that measured when using collapsed GVs as a blank. However, for some 
samples containing GVs that are fluorescent, it is necessary to use the collapsed GVs as the 
blank.
! CAUTION Before doing manual collapse, ensure that the tip-cap on the syringe is facing 
away from you and securely fastened, as pressurization of the syringe may cause ejection of 
the cap, resulting in potential injury to the user. Wear protective eyewear and clothing.
▴CRITICAL STEP It is important to ensure that the GVs are homogenously re-suspended 
in solution just before measurements. For each sample, take the average OD500,ps value after 
multiple measurements (n>=3) to ensure precision and accuracy.
Quantification of GV protein concentration ● TIMING 15 m: 3| Measure the protein 
concentrations using the Pierce 660nm protein assay to obtain relationships between optical 
density and protein content for the GV solutions. We have established the protein 
concentrations to OD relationships of our three types of GVs, and the results are as shown in 
Table 3 below (N = 4, 5, 3 for Mega, Ana and Halo GVs respectively and the errors are in 
SEM). The molecular weight is derived from the TEM data summarized in Table 4, 
assuming a spindle shape for Halo GVs, a cylindrical shape for Mega and Ana GVs, a wall 
thickness of 18 Å and a protein density of 1.4 g/mL.
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Chemical functionalization of GVs ● TIMING 2 d: CRITICAL Purified Ana, Halo and 
Mega GVs contain lysine residues on the surface that can be used to chemically conjugate a 
variety of moieties such as polyethylene glycol, fluorophores and biotin using an amine-
reactive coupling group such as N-hydroxysuccinimide ester.
4| Measure the concentration of purified GVs using the OD relationships in Table 2.
5| Aliquot the NHS-moiety in anhydrous DMSO at 100x of the required molar concentration 
for the amine-NHS reaction. For Alexa-488-NHS conjugation to Ana GVs, aliquot 5 μl of 
the 10 mM stock solution of the dye pre-prepared in anhydrous-DMSO.
▴CRITICAL STEP Ensure that the NHS-moiety solution does not contain detergents or 
surfactants that might affect the integrity and properties of GVs.
6| Adjust the concentration and volume of GVs to the desired amount and ensure that the 
buffer is free of amines (avoid Tris buffer). For Alexa-488-NHS conjugation to Ana GVs, 
bring Ana GVs to OD1 in 1 mL of PBS at pH 7.4.
▴CRITICAL STEP If GVs were previously in a buffer containing free amines or PBS with 
pH less than 7, ensure complete buffer exchange with PBS at pH 7 – 9 before proceeding 
with the amine-NHS reaction.
7|Add 105 molar excess of the NHS-moiety to GVs, keeping the DMSO concentration at 
0.5% or less of the total reaction volume. For Alexa-488-NHS conjugation to Ana GVs, add 
5 μl of the 10 mM Alexa-488-NHS in DMSO to 1 mL of Ana GV solution. Based on the 
average number of gvpA and gvpC protein monomers that make up Ana GVs, 
approximately 50,000 lysine residues are present for every Ana GV. One can tune the molar 
ratio of the two reactants (NHS-moiety:GV) to achieve the desired reaction efficiency.
8| Allow the reaction to proceed for 4 hours at room temperature under gentle rotation.
?TROUBLESHOOTING
9| Quench the unreacted NHS-moieties using Tris-HCl buffer at pH 8 to a final 
concentration of 10 mM for 20 minutes at room temperature under gentle rotation
10| Add the whole reaction to dialysis tubes (6–8 kDa cutoff) and dialyze against a 4000x 
volume excess of PBS at 4˚C for 8 hours. Replace the buffer and allow dialysis to continue 
for an additional 8 hours.
CRITICAL STEP If NHS-moiety is not amenable to dialysis, repeated rounds of 
centrifugally-assisted purification is an alternative method to remove excess reactants and/or 
for buffer exchange.
?TROUBLESHOOTING
▪ PAUSE POINT Chemically functionalized GVs can be stored in PBS buffer for up to one 
year at 4˚C −.
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Optional: Genetic modification and functionalization of Ana GVs ● TIMING 3 days: 
CRITICAL The outer scaffold protein of Ana GVs, gas vesicle protein C (GvpC), can be 
removed and replaced with genetically modified recombinant versions as a molecular handle 
for GV mechanical modification and functionalization. This procedure comprises stripping 
native GvpC off Ana GVs (Steps 11–19), preparing recombinant GvpC (Steps 20–38) and 
re-adding this GvpC onto ∆GvpC Ana GVs via dialysis (Steps 39–41). In addition, GVs 
functionalized with GvpC fused to the SpyTag peptide enable convenient downstream 
covalent functionalization with proteins fused to the SpyCatcher moiety (Steps 42–45).
11| Preparation of ∆GvpC GVs (Steps 11-19: ● TIMING 12 h) Dilute purified Ana GVs 
in PBS such that OD500,ps <10.
12| Prepare 3:2 (vol/vol) mix of GV stripping buffer (10M urea in 100mM Tris buffer) and 
GV solution in PBS. Pipet 1.7 mL into 2 mL microcentrifuge tubes.
13| Centrifuge at 300g for 4 hours, or until the subnatant is completely clear. Remove the 
clear subnatant with a syringe using a 21G flat needle. Retain the milky white supernatant in 
the tube. Resuspend the GV-containing supernatant in GV stripping Buffer (Round 2 i.e. 6M 
urea, 60mM Tris-HCl). Repeat this step 1 time.
14| Confirm GvpC removal by performing SDS-PAGE. Incubate a 1:1 (vol/vol) mix of GVs 
in 2x Laemmli buffer (containing 5% (vol/vol) 2-mercaptoethanol) at 95°C for 5 m. 
Centrifuge briefly to collect condensate.
15| Assemble the electrophoresis cell with the comb and tape removed from the 
polyacrylamide gels. Fill the inner chamber completely with 200 mL 1x TGS buffer. Ensure 
that the cell is not leaking fluid. Fill the outer chamber up to mark with 600 mL 1x TGS 
buffer.
16| Load the protein ladder and samples in the gel using gel-loading tips. GVs should be at 
OD500 > 3 prior to the 1:1 dilution. If purified proteins are being run on the same gel for 
comparison, load > 100 ng.
CRITICAL STEP In order to prevent contamination between wells, do not exceed the 
maximum recommended volume per well.
17| Connect electrophoresis cell to power supply and run the gel for 55 m at 120V.
18| Recover the gel by disassembling the electrophoresis cell and the gel cassette. Incubate 
the gel in a holder with DI H2O for 10 m, then stain for 1 h with 10 mL SimplyBlue™ 
SafeStain. De-stain the gel for at least 1 h with 10 mL DI H2O.
19| Image the gel using a Coomassie imaging protocol using the gel imaging system to 
visualize protein bands. The GvpC band at approximately 25 kDa should be missing.
▪ PAUSE POINT Store the ΔGvpC GVs in urea buffer at 4°C for no more than 1 week. 
When preparing ΔGvpC GVs for long term storage without any further genetic 
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functionalization or recombinant GvpC addition (steps 39–45), we recommend dialyzing the 
GV solution against PBS in order to completely remove the urea.
?TROUBLESHOOTING
20| Preparation of recombinant GvpC (Steps 20-38) :● TIMING 1 d) Transform > 1 ng 
pure plasmid encoding recombinant GvpC with a C-terminal hexahistidine tag into BL21 
(DE3) competent cells and grow culture in terrific broth with 50 μg/ml kanamycin overnight.
21| Dilute 500 μL of the starter culture 1:1 with 50% glycerol in water and store at −80°C. 
Future starter cultures can be grown from aliquots of this glycerol stock instead of fresh 
transformations.
22| Dilute starter culture 1:250 in terrific broth with 50 μg/ml kanamycin and grow to 
OD600~0.4–0.7 with shaking (250 rpm) at 37ºC. Induce at a final concentration of 1mM 
IPTG. Grow culture for 6–12 h at 30ºC with shaking.
CRITICAL STEP Frozen IPTG stocks should be thawed fully and vortexed to mix contents 
before use.
23| Pellet the cells in ultracentrifuge tubes at 5,500g for 15 min at 4°C and discard the 
supernatant.
▪ PAUSE POINT Cell pellets can be stored at −20°C. Protein extraction is typically more 
effective with frozen cells.
24| Resuspend the pellets in 10 mL Solulyse with 10 μg/mL DNAse. Rotate at room 
temperature for 10 min.
25| Centrifuge at 20,000g for 15 m at 4°C to clear the lysate and discard the supernatant.
26| Resuspend the pellet in 10mL Solulyse and lysozyme (0.25 mg/mL). Rotate at room 
temperature for 10 m.
27| Add 5mL Solulyse and vortex. Centrifuge at 20,000g for 20 m at 4°C and discard the 
supernatant.
28| Thoroughly resuspend the pellet in 5 mL of inclusion body solubilization buffer.
29| Centrifuge at 20,000g for 20 m at 4°C.
30| Add 1.5mL Ni-NTA slurry to the supernatant, incubate at 4°C with shaking (60 rpm) for 
2 h or more.
31| Pour into a polyprep column and collect all the flow-through, wash and elutions in the 
next steps. Collecting all fractions is good practice for troubleshooting and analyzing 
purification steps using SDS-PAGE.
32| Wash with 10 column volumes of inclusion body wash buffer.
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33| Elute with 2 column volumes of inclusion body elution buffer.
34| To quantify the eluted protein using the Bradford assay, prepare a standard curve of 
bovine serum albumin (BSA) at a final concentrations of 100, 250, 500, 750, 1000 and 1500 
μg/mL in 60 μL of 3x diluted inclusion body elution buffer in PBS. Prepare dilutions of 
eluted protein 1:2 in PBS with a final volume 60 μL. Prepare a negative control of 3x diluted 
inclusion body elution buffer in PBS.
35| To 25 μL of the sample and BSA standards, add 1 mL of Bradford reagent, vortex and 
incubate at room temperature for 5–10 m. Prepare all samples in duplicate.
36| Blank the spectrophotometer with a negative control sample and measure the OD595.
37| Measure the OD595 of the standard curve samples. Plot the OD595 versus the 
concentration, and compute linear regression fit.
38| Measure the OD595 of the eluted protein samples. Use the linear fit from Step 37 to 
compute the unknown concentrations, and multiply by 3 (dilution factor) to obtain 
concentration of stock elution solution.
▪ PAUSE POINT Store the elutions separately at 4°C. Elution 1 has > 80% of collected 
pure protein and is used for the subsequent experiments. Elution 2 is more dilute and is 
typically stored as backup or for running protein controls for SDS-PAGE.
?TROUBLESHOOTING
39| Preparation of GVs with recombinant GvpC (Steps 39-41● TIMING 1 d) Add 
recombinant GvpC to ∆GvpC GVs according to the formulation: 2 * OD * 198 nM * 
volume (in L) of GVs = nmol recombinant GvpC. This provides a 2-fold stoichiometric 
excess of GvpC relative to binding sites on an average Ana GV, assuming a 1:25 molar ratio 
of GvpC : GvpA binding based on previous work. The exact volume of recombinant GvpC 
to be added is calculated based on the molar mass of the particular variant and the 
concentration of eluted GvpC (measured by Bradford according to steps 34–38). For 
truncated GvpC variants with a lower GV binding affinity, a higher stoichiometric excess 
may be added to promote attachment of GvpC to the GV surface. However, note that adding 
too much excess of GvpC might lead to protein aggregation during dialysis.
40| Soak the dialysis tubing in PBS for 5 minutes. Add samples (GVs + recombinant GvpC) 
into dialysis tubing and clip both sides. Dialyze in 4L PBS with stirring on low speed for at 
least 12 h. CRITICAL STEP The length of dialysis tubing used for each sample depends 
on the total volume of the dialysate, which is determined by the amount of engineered GVs 
required for the end application. The type of dialysis tubing used (molecular weight cutoff) 
can change depending on the GvpC variant, as truncated variants may have a much lower 
molecular weight.
41| Transfer the dialysate into 2-mL centrifuge tubes and spin at 300g for 3 hours, or until 
subnatant is clear. Remove subnatant with syringe with a 21.5G flat needle. Retain the milky 
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white supernatant in the tube. Resuspend GVs in PBS. Repeat this centrifugation step one 
time.
▪ PAUSE POINT Store at 4°C.
?TROUBLESHOOTING
42| Optional: Preparation of SpyCatcher-functionalized GVs (Steps 42-45: ● TIMING 
5 h) Prepare Ana GVs with GvpC fused to SpyTag peptide using Steps 39–41.
43| Mix SpyTag-functionalized GVs with SpyCatcher-fused proteins according to the 
formulation: 2 * OD * 395 nM * volume (in L) of SpyTag GVs= nmol SpyCatcher-fused 
protein. This results in a 2-fold excess of SpyCatcher to SpyTag in the reaction, based on the 
stoichiometry described in Step 39. Note that the SpyCatcher-mNeonGreen (SC-mNG) 
fusion protein used in our published work is expressed separately in E.Coli following 
procedures in Steps 20–23 and using the plasmid containing SC-mNG (details in the 
reagents section). SC-mNG is expressed as a soluble protein and hexahistidine-tagged, 
enabling purification using the same Ni-NTA slurry used for recombinant GvpC purification. 
Unlike GvpC inclusion bodies, soluble proteins are in the supernatant after cell lysis with 
Solulyse/DNAse (Step 24), allowing direct incubation of the supernatant with the slurry 
(Step 30). Wash and elution (Steps 31–33) are performed with soluble protein wash buffer 
and soluble protein elution buffer respectively, and the protein is desalted into PBS using 
PD10 desalting columns. Protein quantification is done using the Pierce or Bradford assay 
before use.
44| Incubate 1 hour or more at room temperature.
45| Centrifuge at 300 g for 3 hours or until subnatant is clear. Remove clear subnatant with 
syringe with 21.5G needle. Retain milky white supernatant in the tube. Resuspend 
supernatant in PBS. Repeat this centrifugation step one time.
▪ PAUSE POINT Store at 4°C.
?TROUBLESHOOTING
GV Characterization: 46| To characterize the purified GVs, follow the procedure in A to 
determine the critical collapse pressure of GVs using pressurized absorbance spectroscopy. 
Follow option B for DLS measurements and option C for preparing the GV specimens for 
TEM.
(A) Determining critical collapse of GVs with pressurized absorbance 
spectroscopy ● TIMING 40m
(i) Before acquiring measurements, connect the spectrophotometer to a power 
supply for 30 m to allow it to warm up.
(ii) Run the Alicat_startup script to initialize the pressure controller.
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(iii) Blank the spectrophotometer with a cuvette filled with PBS or GV resuspension 
buffer and run OceanOptics_startup_FullTrans to save the data.
(iv) Establish a zero-transmission baseline with the opaque side of cuvette blocking 
the light path using the OceanOptics_startup_NoTrans script.
(v) Fill cuvette with intact GV sample (OD500nm = 0.2 in PBS) and fasten the 
cannulae securely. To assist loading, use elongated gel-loading micropipette tips.
(vi) Open the N2 tank valve, pressure regulator, and pressure controller valve.
(vii) Run the Collapse script to measure the OD500,ps under increasing hydrostatic 
pressure (0 kPa – 1.4 MPa in 20-kPa increments).
(viii) Between these measurements, rinse the cuvette with DI H2O, 70% ethanol and 
acetone to ensure that cuvette is completely clean and dry before adding the next 
sample.
(ix) After measurements, close gas the valves and turn off the spectrophotometer.
?TROUBLESHOOTING
(B) Preparation of GV specimens for dynamic light scattering (DLS) ● 
TIMING 5 m
(i) Dilute the GV samples to OD500,ps = 0.2 in PBS.
(ii) Measure the particle size on ZetaPALS instrument with an angle of 90° and 
refractive index 1.33.
(C) Preparation of GV samples for transmission electron-microscopy (TEM) 
● TIMING 30 m
(i) Buffer-exchange the purified GVs in 10 mM HEPES buffer with 150 mM NaCl 
or an alternative non-phosphate containing buffer via centrifugally-assisted 
floatation (same procedure as used for GV isolation) at 8°C and 300g. Replace 
the subnatant with equal volume 10 mM HEPES buffer with 150 mM NaCl. 
Repeat 3 times. The aim of this step is to prevent phosphate in the PBS from 
causing unwanted precipitation of the uranyl acetate stain used downstream in 
step (vi). Therefore, if the GV solution is very concentrated, direct dilution of 
the GV sample into the above-mentioned HEPES buffer to a final OD of 0.2 
would be a quicker alternative.
(ii) Dilute the GVs to a final OD of 0.2.
(iii) Spin 2% Uranyl acetate solution in a benchtop centrifuge at 14,000xg for 5 
minutes to pellet any precipitate.
(iv) Charge Formvar TEM grids using the glow discharge system with 15 mA 
current for 1 minute.
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▴CRITICAL STEP Gently handle the TEM grids and avoid contact of the 
tweezer tip with the center of the grid to prevent bending and damage to the 
grids.
(v) Place 2 μl of well-mixed GV solution on the charged Formvar TEM grids for 3 
minutes. The sample should be placed on the carbon side of the grid; avoid 
placing sample on the copper side. For convenience, we use PELCO reverse, 
anti-capillary tweezers to hold the TEM grid while adding sample and negative 
stain.
(vi) Add 5 μl of 2% uranyl acetate to the GV solution on the TEM grid for 30 
seconds.
(vii) Using a Whatman filter paper, wick the solution by gently touching the edge of 
the grid. For consistent results, leave a thin film of sample on the grids and leave 
to air dry.
(viii) Image the grids using TEM.
?TROUBLESHOOTING
Ultrasound imaging of GVs in vitro in agarose phantoms: 47| Agarose phantom 
preparation and sample loading (Steps 47–55: ● TIMING 3 h) Make a 250 mL solution 
of 1% (wt/vol) agarose in PBS and microwave for 3 minutes to ensure dissolution. Ensure 
that the lid is loosely fastened and swirl the bottle at 1 min intervals to prevent the agarose 
from settling.
48| Fasten the lid and put the bottle in a water bath at 50–55°C for at least 30–45 min to 
allow the solution to equilibrate to the bath temperature
49| Fill the Nalgene plastic holder (L 12.5 cm x W 8 cm, 300 mL) with 150 mL of molten 
1% agarose in PBS. Keep the remaining agarose solution in the water bath for sample 
loading.
50| Immerse the multi-well phantom mold on top of the agarose solution.
▴CRITICAL STEP Remove any small air bubbles with a syringe needle and lower the 
mold gently onto the surface of the agarose, maintaining a small angle to allow any air 
trapped on the interface between the agarose and mold to escape.
51| Let the agarose phantom solidify at room temperature for 1 h.
52| Carefully take out the multi-well phantom mold without disturbing the agarose beneath.
53| Prepare the GV samples and controls at 2x of the final desired concentration.
54| Prepare a 1:1 mixture of the 1% agarose in PBS with the GVs or polystyrene beads.
▴CRITICAL STEP Make sure the 1% agarose in PBS is equilibrated to a temperature of 
50–55°C before and during the mixing with GVs or polystyrene beads. Just prior to mixing 
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with the agarose, place the GV or polystyrene sample for 10–15 seconds in a 50°C water 
bath to warm the sample. This allows proper mixing of agarose with the sample and 
provides enough time to load the sample into the well before the agarose solidifies.
CRITICAL STEP Do not heat the GV samples to temperatures above 50°C. GV collapse 
has been observed even for a 10–20 sec incubation at 65°C or above.
55| Pipette the mixture into the phantom well. The volume of mixture pipetted depends on 
the dimensions of the well, typically 50–100 μL.
?TROUBLESHOOTING
56| Phantom imaging (Steps 56–62: ● TIMING 1 h) Place the ultrasound acoustic 
absorber at the bottom of the phantom holder to prevent multiple ultrasound wave reflections 
during the measurement
57| Immerse the phantom in water or 1X PBS
58| Perform ultrasound imaging on the Verasonics L11–4v or L22–14v ray-line example 
scripts using the following parameters: set the transmit frequency is to 4.5 MHz, set the 
number of cycles of the transmitted ultrasound pulse to 3, the F-number to 3, the voltage to 
2.5 and the persistence to 90. These parameters can be adjusted by the user in the Verasonics 
MATLAB script defining the ultrasound pulse sequence, and operated via the VSX GUI. 
Perform the collapse using a high power pulse at 25V.
59| Perform ultrasound imaging at the fundamental frequency with the L22–14v: the 
transmit frequency is set to 11.5 MHz, the number of cycles of the transmitted ultrasound 
pulse is set to 6, the F-number to 2, and the voltage to 3V. Those parameters are adjusted in 
the script and operated via the VSX GUI.
60| Perform ultrasound imaging at the second harmonic frequency with the L11–4v 
transducer: echoes at the second harmonic frequency are displayed using a 2 MHz wide 
band pass filter centered around 9 MHz. Other parameters are identical to the fundamental 
imaging mode and adjusted in the script. Second harmonic imaging is operated as an option 
via the VSX GUI. Note that we have recently developed an amplitude modulation strategy 
that can also be used for highly selective non-linear imaging of native and engineered GVs.
61| Obtain acoustic multiplexing images by using GVs at OD 1 and a transmit frequency of 
6.25 MHz and at 1.6V on the L11–4v, with a 4 cycle pulse, transmit focus of 20 mm, F-
number of 2 and persistence of 90. To collapse the GVs, increase the acoustic pressure by 
lowering the F-number to 0.1 and gradually ramping up the voltage. At each collapse step, 
the transducer is translated in the y and z planes using the Velmex motors to ensure 
homogenous collapse over the entire well and field of view.
62| Save the ultrasound images for subsequent processing as .fig images (MATLAB format) 
directly from the MATLAB figure panel.
?TROUBLESHOOTING
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Ultrasound imaging of GVs in vivo: 63| GVs can be used as contrast agents for in vivo 
ultrasound imaging. Option A describes the steps for imaging GVs in mice using the 
Verasonics system, while Option B describes the procedure for imaging Halo GVs using the 
Vevo ultrasound system.
CAUTION Any experiments involving live mice must conform to relevant Institutional and 
National regulations. All animal experiments reported in this article received approval from 
the Institutional Animal Care and Use Committees of the California Institute of Technology 
or the Sunnybrook Research Institute.
(A) GV imaging in vivo using the Verasonics ultrasound system ●TIMING 45 
m
(i) Place the mouse in the induction chamber with isoflurane 3–4%, room air at 2 
liters/min with the vacuum on for isoflurane removal.
(ii) When the animal is unresponsive to toe pinch, move the animal to the heat pad 
and nose cone for continued anesthesia and place it on the supine position. 
Reduce the isoflurane to 2% and apply eye lubricant to both eyes to avoid 
drying. Use NAIR™ and cotton swabs to depilate the abdominal area and wash 
thoroughly with saline to avoid any burns on the skin.
(iii) Prepare the catheter using 10 cm of PE10 plastic tubing and a 30 G needle. With 
a razor blade, cut the plastic at the bottom of the needle to allow the blunt end to 
be free. Push this end into the PE10 plastic tubing.
!CAUTION Follow safe practices and wear proper PPE while handling sharp 
needles.
(iv) Fill the catheter with saline using a 30 G syringe. Confirm that there is no 
leaking from the catheter. Remove the saline-filled syringe before the next step.
▴CRITICAL STEP Failure to fill the tubing with liquid to remove the air from 
the catheter can lead to a gas embolism and death of the animal.
(v) To insert the catheter into the tail-vein, place the mouse on its side for a better 
view of the lateral tail vein, clean the tail with an alcohol swab. Using the 
dominant hand to hold the catheter, use the other hand to hold the tail between 
your thumb and index finger. Insert the bevel needle through the skin and into 
the vein at a flat angle and advance it for several mm. If the needle is inserted 
correctly, blood should backflow through the catheter.
(vi) Secure the position of the catheter in the tail vein with tissue adhesive glue and 
use the 30G syringe filled with saline to flush the blood from the catheter.
CRITICAL STEP The flow of saline should be smooth, confirming proper 
positioning of the needle tip in the tail vein. Excessive pressure to achieve flow 
may indicate improper positioning of catheter or clotting of blood.
(vii) To perform ultrasound imaging, slowly adjust the mouse to a supine position and 
apply ultrasound gel on the depilated area. Place the transducer on the gel.
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CRITICAL STEP Make sure that there are no air gaps and that the gel is 
completely coupled to the transducer.
(viii) Open the Verasonics L11–4v ray-line example script in MATLAB . The transmit 
frequency is set to 4.5 MHz with the L11–4v transducer. Position the transducer 
to see the Inferior vena cava (IVC) for vascular imaging. Keep the voltage at 
2.5V, 3-cycle pulse, F-number 3 and persistence 20.
▴CRITCAL STEP Ensure that the region of interest in the mouse aligns with 
the focus of the transducer to acquire optimal images.
(ix) (ix) Remix the gas vesicles thoroughly by gently pipetting up and down, then 
aliquot 100 μL of solution of OD500,ps ~ 25 into a 1.5 mL micro-centrifuge tube.
▴CRITCAL STEP Gas vesicles must be mixed thoroughly each time before an 
injection, they are buoyant and will float up to the top of the tube. Make sure to 
inject immediately after remixing.
(x) Carefully load a 30 G tuberculin syringe with the GV solution, making sure 
there are no air bubbles. Do not tap as this may collapse the GVs. Replace the 
saline-filled syringe at the end of the catheter and secure it to the syringe pump.
(xi) Fill the catheter line with GVs at a rate of 5 μL/s.
(xii) Inject 50 μL of GVs into the tail vein at a rate of 5 μL/s and record the 
ultrasound signal appearing in the IVC and liver.
▴CRITCAL STEP The total amount of injected saline and sample should be 
monitored and within the approved safety guidelines to prevent adverse effects 
on the animal caused by blood dilution.
(xiii) Perform imaging using B-mode or harmonic filtering as described in steps 58–
60 for in vitro specimens.
(xiv) At the end of the imaging session, turn off the isoflurane and remove the mouse 
from the nosecone. Wait for the animal to completely recover from the 
anesthesia before returning it back to the cage.
?TROUBLESHOOTING
(B) Halo gas vesicle imaging in vivo using the Vevo ultrasound system 
●TIMING 45 m
(i) Setup the ultrasound mouse imaging station (see ‘ Setting up the Vevo Imaging 
Station’ in Equipment Setup) and attach the 21 MHz, MS250 MicroScan™ 
Transducer to the probe clamp. Make sure that the transducer is placed in the 
active port of the Vevo®2100 system.
(ii) Adjust your ultrasound imaging parameters (see ‘Setting imaging parameters on 
the Vevo®2100 system’ in Equipment Setup) for both B-mode and nonlinear 
contrast mode imaging.
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▴CRITICAL STEP Ensure that all imaging parameters are kept the same, so 
data can be compared across animals.
(iii) Warm the mouse for 5 – 10 minutes to dilate its blood vessels. Care should be 
taken to not over heat the animal.
!CAUTION Heat lamp can get very hot. Handle with care.
(iv) After the animal has been warmed up, anesthetize for tail vein cannulation. Mice 
are anesthetized using a tabletop animal anesthesia system. Place the mouse in 
the induction chamber and open the valve of the medical air cylinder. Set the 
flow meter to 1.5 L/min and vaporizer to 5% isoflurane.
(v) After 1–2 minutes transfer the mouse to the handling table and re-route the 
anesthesia from the induction chamber to the nosecone. Fit nosecone over the 
nose and mouth of the mouse. Toe pinch to make sure there is no reflex, then 
lower the vaporizer to 2% for maintenance.
▴CRITICAL STEP Use medical air instead of oxygen as the carrier for the 
isoflurane to increase the stability of gas vesicles.
(vi) Fill a 1mL syringe with a 27G x 1/2 needle with 0.9% sodium chloride solution, 
and attach the end of the catheter tubing to the needle.
(vii) Flush the catheter tubing with the 0.9% sodium chloride solution until the 
solution leaks out from the catheter needle.
▴CRITICAL STEP Failure to fill the tubing with liquid to remove the air from 
the catheter can lead to a gas embolism and death of the animal.
(viii) Insert catheter into tail vein as described in step 63A(v).
(ix) Place eye ointment in both eyes of the mouse to prevent drying.
(x) If desired, heart rate and respiratory rate monitoring can be accomplished as 
follows: place a small amount of electrode gel onto the 4 electrodes located at 
the corners of the mouse handling table, and secure each paw of the mouse to 
the electrodes with surgical tape. Make sure the animal is placed in a supine 
position to allow for ultrasound probe access to the liver. Refer to Figure 4d.
(xi) For body temperature monitoring, lubricate the temperature probe and insert 
gently into the rectum of the animal. Refer to Figure 4d.
(xii) Apply ultrasound gel to the upper abdominal region of the mouse, right below 
the rib cage, and place the transducer on top of the gel.
(xiii) Starting with B-mode imaging, adjust the X, Y and Z positioning knobs to locate 
a slice of the liver where the inferior vena cava (a), portal vein (b) and 
abdominal aorta (c) can be observed in the same imaging plane. Once an 
imaging plane has been established, switch the imaging mode over to nonlinear 
contrast.
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(xiv) Resuspend the gas vesicles thoroughly by gently pipetting up and down, then 
aliquot 60 μL of solution (50 μL for injection + 10 μL to fill catheter tubing) into 
a 1.5 mL micro-centrifuge tube. We typically use OD500,ps ~ 5 for Halo 
injections, although one can go higher or lower based on their experimental 
needs and design (injected concentrations as low as OD500,ps 1.5 can be detected 
in the IVC).
▴CRITICAL STEP Gas vesicles must be mixed thoroughly each time before an 
injection, they are buoyant and will float up to the solution surface very quickly. 
Make sure to inject immediately after remixing.
(xv) Withdraw the aliquoted gas vesicle solution into a 1/2cc tuberculin syringe and 
secure into the syringe pump. With the needle pointing up, remove any bubbles 
by gently pulling the plunger down and up. Do not flick the syringe as this will 
collapse GVs.
(xvi) Imaging under nonlinear contrast mode, acquire ultrasound images before, 
during and after a bolus injection of gas vesicles, to observe the change in signal 
from the inflow of gas vesicles. A high power burst sequence can also be applied 
to collapse any gas vesicles in the imaging plane and diminish the signal.
? TROUBLESHOOTING
(xvii) Steps xiii - xv can be repeated for other tissue regions of interest.
(xviii) At the end of the imaging session, turn off the isoflurane and remove the mouse 
from the nosecone. Wait for the animal to completely recover from the 
anesthesia before returning it back to the cage.
GV imaging using 129Xe-MRI in vitro ● TIMING 2–3 h
64. Preparing GV samples for MRI: Dilute the stock solution of GVs in 
phosphate-buffered saline solution to achieve an OD500, PS of ca. 0.33. For each 
sample, 2 mL of GVs are needed.
▴CRITICAL STEP While Ana and Mega GVs are stable and survive multiple xenon re-
deliveries and data sets, Halo GVs are very fragile. Therefore, use a fresh Halo sample for 
each measurement.
OD measurements should be performed before and after NMR measurements to ensure GV 
concentrations stay constant.
65. Starting up the polarizer (Steps 65–72:● TIMING 20 m) Turn on the 
hyperpolarizer according to the manufacturer’s protocols.
66. Select an absolute gas pressure in the system of ca. 1.2 bar (i.e. 0.2 bar above 
atmospheric pressure). This pressure is adjusted through the Daq/Board-
regulated pressure controller behind the sample and will be reached once the 
hyperpolarizer outlet valve has been opened. The manual pressure regulator 
directly at the gas tank should be set to a higher value (1.5 to 2 bar).
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▴CRITICAL STEP Since the GVs are pressure sensitive, an excessive pressure 
set point for the sample could later damage the GVs in solution when 
performing step 76. On the other hand, the gas pressure determines the amount 
of dissolved Xe and eventually the image signal intensity. Considerations 
regarding the expected spin concentrations are described in Box 1.
67. Connect the gas delivery tubing (coming from the hyperpolarizer) with the gas 
outlet tubing (going into the pressure controller) using glass connecting tube 
shown in Figure 5b.
68. Slowly open the outlet valve of the hyperpolarizer to pressurize the gas manifold 
and to achieve the selected total pressure of 1.2 bar in the entire system.
! CAUTION Back-flow of air (oxygen) or humidity into the system and the Rb-
containing optical pumping cell in the polarizer setup must be avoided at any 
time to prevent violent reactions with the reactive Rb.
69. Select a total gas flow rate of 250 SMLM through the system for the flow 
controller between the gas tank and the hyperpolarizer. The pressure controller 
will now maintain the 1.2 bar while releasing incoming excess gas at the 
selected flow rate.
70. Wait until the process temperatures have reached a steady state.
71. Stop the gas flow by setting the flow controller set point to 0 SMLM and isolate 
the hyperpolarizer by closing its outlet valve.
72. Depressurize the gas manifold by carefully unscrewing the glass tube connector 
while keeping the polarizer in standby.
73. Checking the gas delivery conditions (Steps 73-82)● TIMING 10 m Decide 
if the glass phantom should be used with a one compartment for a single sample 
solution or with two compartments for including a second solution (e.g., a 
reference buffer solution without GVs); in the latter case, insert a 5mm NMR 
tube into the glass phantom.
74. Load the sample solution(s) into the glass phantom and screw the capillary 
holder onto the inlet thread (distribute the capillaries as needed between the two 
compartments in case the 5mm tube has been inserted). Make sure that the 
filling level is not too high, so that the NMR coil can also detect some of the gas 
atmosphere on top of the solution.
75. Connect the gas delivery tube from the hyperpolarizer setup to the capillary 
holder of the phantom and the gas outlet tube to the other chem thread of the 
glass phantom.
76. Select a total flow rate through the polarizer of 250 SMLM and activate the flow. 
This will ensure that gas is flowing into the system once the next step is 
performed.
77. Carefully pressurize the PFA tubing system by slowly opening the outlet valve 
of the hyperpolarizer to reach the overpressure of 0.2 bar.
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CRITICAL STEP Make sure the shortcut valve is always open for pressurizing 
or depressurizing the sample; this avoids abrupt pressurization that could push 
the sample solution out of the glass phantom into the PFA tubing which can later 
contaminate the flow or pressure controller.
▴CRITICAL STEP When pressuring the GV-containing sample with xenon gas 
mix, a fast change in pressure has to be avoided and a rate of 0.1 bar/30 seconds 
should not be exceeded to ensure the GVs remain intact.
78. Once the pressure has stabilized, ensure that the total flow rate of 250 SMLM 
through the polarizer is still active while the shortcut valve is open; this flow will 
now go through the bypass without bubbling the sample.
79. To bubble the sample, adjust the sample delivery flow to 40 SMLM.
80. For activating the flow, the pulse sequence needs to be executed. However, all 
RF pulses should be turned off since there is no sample in the NMR coil that 
absorbs the transmitted power. To do so, select first the pulse-acquire FID 
sequence including the TTL triggers and set the amplitude of the excitation 
pulse to 0.
81. Choose a bubble time of ca. 10–20 sec and a waiting time after bubbling of ca. 
1–2 sec.
82. Set the number of repetitions to 5–10 and start the sequence while watching the 
sample for sufficient gas dispersion during periodic gas delivery and possible 
unwanted excessive foam formation inside the glass phantom. Ensure that any 
foam and gas bubbles disappear within the waiting time after bubbling (typically 
1–2 sec).
▴CRITICAL STEP Prolonged bubbling could collapse GVs via shear forces. 
The flow of gas through the sample should be long enough to have decent xenon 
signal but short enough to not stress the GVs too much. The subsequent waiting 
time should be as short as possible to minimize the longitudinal relaxation of the 
xenon while long enough to ensure all bubbles to collapse.
? TROUBLESHOOTING
83. Preparative MRI measurements (Steps 83-91:● TIMING 10 m) Insert the 
pressurized phantom carefully into the NMR probe that is already mounted 
inside the magnet in its correct position.
84. If desired, adjust the temperature of the sample with the VTU of the 
spectrometer. This sample data was acquired at room temperature (T = 298 K).
▴CRITICAL STEP If another set point, e.g. body temperature, is chosen, the 
sample might need 20–40 min to reach stable temperature. It is possible to 
continue with the next steps, but step 87 () should not be performed until stable 
conditions are reached.
85. Tune and match the 1H and 129Xe resonators, perform a global automatic shim 
on the sample and acquire a proton reference image with automated adjustments 
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for 1H resonance frequency, reference attenuation (flip angle), and receiver gain 
according to the spectrometer manufacturer’s protocol.
86. Set Xe delivery flow to 40 SMLM, 10 sec bubbling time and 2 sec wait time or 
as optimized in (c).
87. Take a 1D Xe NMR spectrum with the pulse-acquire FID sequence including the 
TTL triggers with ca. 350 ppm bandwidth and four signal averages. If the 
amplitude for a flip angle ~90° is not known, proceed with the steps in Box 2 
(and Figure 6f-i) to determine the reference pulse.
88. Perform Fourier transform and automatic phase correction to display the NMR 
spectrum. Find the resonance frequency of the left intense peak (Figure 6a) and 
use it as the transmitter frequency for further 129Xe MRI acquisition.
? TROUBLESHOOTING
89. For the imaging experiments to follow, enter the reference pulse power into the 
pulse sequence control interface (typically the pulse amplitude for a 1 ms block 
pulse to achieve a 90° flip of the magnetization). Switch to an MRI sequence 
and choose the same bubbling time, wait time and transmitter frequency.
90. Ensure that the excitation for either the EPI or the RARE sequence is effectively 
a 90° pulse and that other sequence parameters are set as in the equipment 
preparation section. The number of acquisitions should be set to one.
91. Run the Xe MRI acquisition without any saturation pulses (deactivate the MT 
module) and without phase encoding gradient (GSP in Bruker’s ParaVision) and 
set the receiver gain such that the maximum incoming signal reaches ca. 30% of 
the full ADC range.
92| For Hyper-CEST MRI acquisition, follow the steps in option A for acquiring an entire 
image series with different saturation offsets for obtaining spectral information of the CEST 
response or option B for acquiring data with only one on-resonant and one off-resonant 
saturation to obtain a single Hyper-CEST image. Spectral information is obtained when 
changing the frequency of the saturation pulse (Figure 6b). This results in a so-called z-
spectrum whose characteristic shape is influenced by xenon’s exchange properties with the 
GV. Option C should be performed if the exact resonance frequency of Xe inside the GVs is 
not known. Images with improved quality can then be obtained subsequently with option F.
(A) Imaging series and z-spectrum ● TIMING 45 m
(i) Select the desired number of frequency offsets and enter the values for the 
offsets. The example data in Figure 6b were taken with 31 offsets covering a 
range from – 300 ppm to + 175 ppm with an increment of ca. 16 ppm.
(ii) Select the saturation power B1 and saturation time tsat. The example here used 
saturation conditions of B1 = 15 μT, and tsat = 5 s.
! CAUTION Ensure that the power limits for the NMR coil are not exceeded as 
this might permanently damage the coil.
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▴CRITICAL STEP It is not useful to choose a saturation time that exceeds the 
T1 relaxation time of Xe in water; the signal loss is then dominated by intrinsic 
relaxation and not by the CEST effect .
▴CRITICAL STEP The choice of the right saturation conditions is crucial for 
optimal z-spectra quality and for correct interpretation of saturation transfer in 
xenon MR images. As a rule of thumb, short but strong saturation is desired 
first. If multiple agents (different GV types in this context) are present, then the 
saturation strength should be reduced and the saturation time should be adapted 
similarly.
(iii) Start the image series acquisition and make sure that the system does not 
perform any auto-adjustments that overwrite any of the previous settings (GOP 
command in Bruker’s Paravision).
▴CRITICAL STEP If the images are acquired individually because the 
operating system does not allow an array of measurements like in Bruker’s 
ParaVision, it is important that all images are taken with the same receiver gain 
and that the system does not automatically re-adjust the receiver gain before 
each acquisition.
(iv) Open the image evaluation tool of the spectrometer software and draw a region 
of interest (ROI) for signal integration in the xenon MR images that were 
acquired for different saturation pulse frequencies.
(v) Plot the signal intensity of the ROI versus the saturation frequency offset to 
obtain the z-spectrum.
? TROUBLESHOOTING
(vi) Analyze the obtained data: the full signal loss for 0 ppm saturation offset is the 
direct saturation of free Xe in solution. The GV-related response is expected 
around −170 to −190 ppm offset. This local minimum in signal intensity 
corresponds to the frequency for the best Hyper-CEST response. Optimum 
conditions for option B are then obtained for choosing this offset for on-resonant 
saturation and its negative value for the off-resonant control image.
▴CRITICAL STEP While the true GV-bound xenon resonance frequency in the 
sample data is at about −170 ppm (green dashed line, Figure 6b), the maximum 
xenon depolarization spectrally appears at a different frequency which is shifted 
towards that of free xenon (blue dashed line) at about −156.5 ppm. This 
difference is caused by so-called spillover between the GV-bound xenon 
resonance and that of free xenon. This would not occur if the Hyper-CEST 
signal between both resonances would recover entirely back to the baseline. Two 
parameters affect the “intensity” of spillover: 1) The exchange regime (given by 
the ratio of the xenon exchange rate and chemical shift difference in Hz), and 2) 
The strength of the saturation pulse B1. To avoid spillover effects, one can use 
GVs with slower Xe exchange or reduce the saturation power.
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(vii) An accurate evaluation is based on normalized z-spectra that also accounts for 
the T1 relaxation. For this purpose, acquire data points with no saturation (i.e. 
setting the saturation time to zero) and negligible relaxation: set the number of 
saturation offsets to 5, the saturation frequency offset to +300 ppm, and –most 
importantly – the saturation power and duration to 0 μT and 0 sec respectively. 
Start the acquisition and draw an ROI in the xenon MR images for signal 
integration.
(viii) Plot the signal intensity of the ROI for the 5 acquisitions; they should be almost 
identical and the average value can be used for normalizing the values of the z-
spectrum obtained in (v).
(B) Single Hyper-CEST image from two saturation frequencies ● TIMING 20 
m
(i) Set the number of saturation offsets to 2.
(ii) Enter the on-resonant saturation frequency offset and the off-resonant saturation 
frequency offset according to the z-spectrum interpretation in step |()92|(A)(vi)).
(iii) Select the saturation power B1 and saturation time tsat. The example here used 
saturation conditions of B1 = 15 μT, and tsat = 5 s.
! CAUTION Ensure that the power limits for the NMR coil are not exceeded as 
this might permanently damage the coil.
▴CRITICAL STEP It is not useful to choose a saturation time that exceeds the 
T1 relaxation time of Xe in water , the signal loss is then dominated by intrinsic 
relaxation and not by the CEST effect.
(iv) Enter the desired number of image averages, i. e. the number of excitations 
NEX, to achieve good signal intensity, e.g. NEX = 16.
(v) Start the sequence which will perform 2 × NEX acquisitions.
(vi) Check the results in the image display software.
(vii) The difference image displaying the areas with the Hyper-CEST response can be 
obtained by subtracting the image with on-resonant saturation from the image 
with off-resonant saturation using the image display software; if desired, 
normalize the difference image by the off-resonant control image .
▴CRITICAL STEP Ensure that the intensity scaling is the same for the two 
images when performing any difference image calculations.
Shutting down the system ● TIMING 10 m
93. Set the flow into the polarizer to 0 SMLM.
94. Close the polarizer gas outlet and shut down the system according to 
manufacturer’s SOP.
95. Ensure that the shortcut valve is open.
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96. Carefully depressurize the phantom by slowly ramping down the set point of the 
pressure controller.
▴CRITICAL STEP Fast depressurizing may damage the GVs and render them 
unusable for future experiments or quality control.
97. Disconnect the sample tube from the PFA tubings and store them for later 
experiments.
98. Turn off the VTU.
●TIMING
GV production and purification—Media preparation: 1 hour
Steps 1Ai-vi 1Bi-iii: Growing Ana and Halo cultures: 2–4 weeks (depending on the type and 
confluency of culture)
Steps 1Avii-xi and 1Biv-vi: Harvesting Ana and Halo GVs: 1 day
Steps 1Axii-xvii and 1Bvii-xi: Isolation and purification of GVs from Ana and Halo 
cultures: 2–3 days
Steps 1Ci-iv: Heterologous expression of Mega GVs in E. coli: 2 days
Steps 1Cv-x: Harvesting and purification of Mega GVs: 2 days
GV quantification—Step 2: Measuring pressure-sensitive OD using Nanodrop: 15 mins
Step 3: Measuring the GV protein concentration: 15 mins
Chemical functionalization of GVs—Steps 4–10: Chemical functionalization of GVs: 2 
days (includes 1 day for dialysis)
Steps 11–19: Preparation of ΔGvpC GVs: 12 hours
Steps 20–38: Preparation of recombinant GvpC: 1 day
Steps 39–41: Preparation of GVs with recombinant GvpC: 1 day
Steps 42–45: Functionalization of SpyCatcher-functionalized GVs: 5 hours
GV characterization—Step 46A: Determining critical collapse with pressurized 
absorbance spectroscopy: 40 mins
Step 46B: GV preparation for DLS: 5 mins
Step 46C: Preparation of GV samples for TEM: 30 mins
Ultrasound imaging of GVs in vitro: Steps 47–55: Agarose phantom preparation and 
sample loading: 3 hours
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Steps 56–62: Phantom Imaging: 1 hour (can be more depending on number of samples and 
mode of acquisition)
Ultrasound imaging of GVs in vivo: Step 63A: GV imaging in vivo using the Verasonics 
ultrasound system: 45 mins
Step 63B: Halo gas vesicle imaging in vivo using the Vevo ultrasound system: 45 min 
(timing may vary based on number of acquisitions)
GV imaging using 129Xe-MRI in vitro: Steps 64–91: Preparing GV sample and MRI 
equipment for data acquisition: 50 mins
Step 92 Option A: Imaging series and z-spectrum: One experimental session: 1.5 hours
Step 92 Option B: Single Hyper-CEST image from two saturation frequencies: One 
experimental session: 1.5 hours
Steps 93–98: Shutting down the system: 10 minutes
?TROUBLESHOOTING
Troubleshooting advice can be found in Table 5.
ANTICIPATED RESULTS:
GV expression and purification
Ana and Halo GV expression and purification:  Healthy, viable Ana and Halo cultures 
look dark green (Figure 2c) and light pink (Figure 2d) upon reaching confluency. Figure 2e 
and f show the separation of buoyant Ana and Halo cells from spent media. For Halo 
cultures, the buoyant cells are visible as a thin layer or ring of milky pink at the top of the 
liquid phase. After lysis, the lysate will appear milky due to the presence of GVs. After one 
round of centrifugally-assisted floatation, the GVs will appear as a white layer at the top 
with a green (Ana) or pink (Halo) liquid subnatant, along with a pellet of cell debris at the 
bottom. For the Halo, a mixed layer of white (Halo GVs) and milky pink (unlysed Halo 
cells) may be visible after the initial spins. Figures 2g and h show representative images of 
the purified Ana and Halo GVs in 2 mL tubes after the final spin, with the white GVs 
forming a dense layer at the top and a clear subnatant of PBS. Figure 2j shows tubes 
containing milky-white solutions of purified Ana and Halo GVs (~OD500,ps 6) resuspended 
in PBS. The typical GV yield is ~ 3 mL of OD500,ps 10 for Ana and Halo GVs per flask of 
culture.
Mega GV expression and purification in E. coli:  While native expression of Ana and 
Halo GVs usually results in majority of the cells being buoyant, most of the E. coli cells 
heterologously expressing Mega GVs reside in the pellet after centrifugation. In our 
experience, the typical yield of Mega GVs is approximately 1.5 mg/L cells per unit OD600. 
Figure 2i shows a representative image of purified and unclustered Mega GVs forming dense 
white layer at the top, with a clear subnatant of PBS. Figure 2j shows a milky-white solution 
of purified and unclustered Mega GVs resuspended in PBS (~ OD500,ps 6).
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GV functionalization—Ana GvpC is purified from inclusion bodies in E.coli. The 
recombinant GvpC can be harvested with yields of up to 8 mg protein / L culture. The 
inclusion bodies yield >95% pure protein (Figure 7a). GvpC-based functionalization relies 
upon complete removal of the native Ana GvpC layer before reconstitution with 
recombinant protein. Urea treatment results in nearly complete (>95%) removal of native 
GvpC, indicated by absence of GvpC on SDS-PAGE (Figure 7a) and a lowered critical 
collapse pressure (shown in the following section on GV characterization).. GVs retain their 
milky white appearance throughout the functionalization process. The binding of 
recombinant GvpC variants to GVs can be assayed by SDS-PAGE and Coomassie staining. 
ΔGvpC Ana GVs do not exhibit a band around 25 kDa (molecular weight of GvpC) while 
wild type and truncated GvpC variants bind to GVs (Figure 7a).
Figure 7b shows an application using dual-functionalized GVs for targeted cell-specific 
imaging. In this example, Ana GVs functionalized with GvpC fused to peptide RGD are 
chemically conjugated to Alexa Fluor 488. The functionalized GVs bind to integrin 
receptors on glioblastoma cells via the RGD motif and the fluorescent labeling of GVs 
enables rapid assessment of targeting efficacy using confocal microscopy. SpyTag-GvpC 
binds to GVs with similar productivity and stoichiometry as wild-type GvpC. We have 
previously shown that each modified GV has an average of 1000 SpyTag functionalities. The 
collapse pressure of SpyTag GVs is not altered upon SpyCatcher binding, indicating that 
attachment of a large 37.9 kD protein to the GV surface does not adversely affect GvpC 
strengthening of the GV wall.
Functionalization of SpyTag-GVs with SpyCatcher-GFP enables multi-modal imaging of 
GVs with ultrasound and fluorescence. Ultrasound images were acquired in an agarose 
phantom with a Verasonics L22–14V transducer at 19 MHz, 5.0 V and F-number 3. The 
ultrasound images show similar echogenicity between fluorescently labeled GVs and wild-
type and unreacted controls (Figure 7c). Optical images taken through the green channel of a 
BioRad Chemidoc MP system indicate that SpyTag-SpyCatcher-GFP labeled GVs are 
fluorescent (Figure 7c). Fluorescence quantification of Halo GVs after chemical conjugation 
to Alexa Fluor 488 indicates that functionalized GVs are around 40-fold more fluorescent 
than native GVs.
GV characterization
Critical collapse pressure of GVs:  The collapse pressure profiles of purified Ana, Halo 
and Mega GVs as well as functionalized GVs are obtained by measuring change in OD500nm 
of GV samples under increasing hydrostatic pressure. The mean collapse pressures are 59 
kPa (Halo), 587 kPa (Ana GvpCWT) and 750 kPa (Mega) (Figure 7d). Ana GVs without 
GvpC have a significantly lower critical collapse pressure of 193 kPa. Collapse pressure 
measurements also indicate the degree of mechanical strengthening by recombinant GvpC 
variants.
DLS Measurements:  DLS values for hydrodynamic diameters exhibit variability due to the 
biogenic nature of GVs. Representative DLS profiles are given in Figure 7e. Hydrodynamic 
diameters of Halo GVs range from 260 nm – 320 nm (polydispersity 0.15 – 0.21), ΔGvpC 
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Ana GVs range from 250 nm – 360 nm (polydispersity 0.21 – 0.24), and GvpCWT Ana GVs 
range from 240 nm – 340 nm (polydispersity 0.17 – 0.26), Mega GVs from 200–380 nm 
(polydispersity 0.23 – 0.34).
TEM visualization of GVs:  GVs appear as bright particles on a dark background under 
negative staining with uranyl acetate. Typically, TEM allows visualization of the 
morphology, size, shape and overall surface features of GVs. Figure 7f shows representative 
TEM images for purified wild-type Halo, Ana and Mega GVs. While Halo GVs appear 
spindle shaped, Ana and Mega GVs are more cylindrical with conical tips in the longitudinal 
dimension. Although the size and shape of GVs are determined primarily by the genotype, 
each type possesses a certain degree of heterogeneity. For example, Ana GVs have length 
distribution with a standard deviation of 35% of the mean. It is also important to note that 
not all Halo GVs have a spindle morphology, and a small subpopulation may appear more 
cylindrical with biconical ends. Ana GVs that are produced in their native host are usually 
longer and wider than heterologously expressed Mega GVs. Typical GV dimensions 
obtained from TEM images summarized in Table 4 (N=107, 125 and 61 for Ana Halo, and 
Mega respectively, errors in standard deviation).
The high resolution provided by TEM allows the visualization of ribs on the surface of the 
gas vesicles at higher magnifications. Figure 7g shows intact and collapsed Ana GVs, 
demonstrating that collapse causes complete rupture and opening of the protein shell, 
leading to a flattened pancake-like structure. GVs chemically functionalized with biotin can 
be coated with streptavidin and visualized by TEM.
In vitro ultrasound imaging: Typical ultrasound images acquired in the fundamental 
mode and after second harmonic filtering show contrast from intact wild-type (WT) and 
ΔGvpC Ana GVs (Figure 8a, top panel). Acoustic collapse of GVs leads to elimination of 
ultrasound signal (Figure 8a, bottom panel), confirming that contrast arises from the intact 
GVs. Lowering of collapse pressure is typically associated with higher non-linear signals 
from GV samples, allowing tuning of GV harmonic response by modification or removal of 
GvpC. The ultrasound contrast from Halo GVs and their utility for nonlinear imaging in 
vitro and in vivo has been demonstrated in our previous work. The acoustic behavior of Halo 
GVs at ultrasound frequencies of 12.5–27.5 MHz has also been investigated through 
modeling and experiments, suggesting acoustic buckling as the mechanism underlying 
generation of non-linear signals. In parallel, we recently developed an amplitude modulation 
scheme taking advantage of the nonlinear pressure dependence of backscattered signals in 
engineered Ana GVs, allowing selective imaging of these nanostructures.
In vivo ultrasound imaging: When imaging gas vesicles in vivo, we suggest starting 
with a vascularized organ such as the liver. A normal liver will look homogeneous under B-
mode ultrasound with vessel cross-sections appearing as hypoechogenic regions (Figure 8b, 
left panel). When imaging a mouse in the transverse plane, it is possible to locate a region of 
the liver containing the inferior vena cava (IVC).
After gas vesicles are administered intravenously via the lateral tail vein, nonlinear contrast 
enhancement will be observed first in the IVC, followed by the liver (Figure 8b). Using the 
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Vevo®LAB software, regions of interests (ROIs) encompassing the IVC and liver can be 
drawn, and a time intensity curve of the mean contrast signal change over time within each 
ROI can be plotted.
As shown in Figure 8c, once a 50μL bolus of gas vesicles has been injected, an initial bulk 
signal is observed in the IVC, which will decrease over times as the gas vesicles are 
dispersed into the circulation. Signal enhancement in the liver will follow a few seconds 
after with a steady signal increase and then a plateau. The signal plateau in the liver is likely 
due to the uptake of non-functionalized gas vesicles by the Kupffer cells, similar to many 
other nano-sized particles. This contrast signal can then be eliminated by employing a high 
power burst that will collapse all the gas vesicles in the imaging plane.
It is possible to engineer Ana GVs to produce enhanced non-linear signals in vivo (Figure 
8d-e). After bolus injection of GVs, ultrasound imaging of the IVC is performed in 
fundamental and harmonic modes for up to a minute (transmission at 4.46 MHz and 
reception filtered around 4.46 and 8.9 MHz center frequencies, respectively). The mean 
signal intensity plotted as a function of time (Figure 8d-e) show that ΔGvpC Ana GVs 
produce higher harmonic signals compared to Ana GvpCWT in vivo, while their fundamental 
signals are comparable. This observation is also consistent with the in vitro data in Figure 
8a.
Hyperpolarized Xe MRI imaging of GVs: Typical GV concentrations in the nano- to 
picomolar range will not allow the observation of the GV-bound Xe directly. A 129Xe NMR 
spectrum therefore only shows the signal from dissolved xenon gas (assigned to 0 ppm) and 
the resonance from Xe gas on top of the solution (appearing ca. 190 ppm right of the 
solution peak) (Figure 6a). Data obtained in step 92|(A)(v) should look similar to the 
spectrum in Figure 6b, except that it is not yet normalized. Taking the relaxation and 
saturation free reference signal from step 92|(A)(viii) into account, the spectrum should 
yield intensities between 0 and 1 like Figure 6b. It should be noted that the longer the 
saturation time, the more the baseline has dropped below 1.
Data from option 92|B can be displayed as the (normalized) Hyper-CEST effect map that 
gives a signal intensity in %. The original data is plotted in Figure 6c-d and the Hyper-CEST 
effect map in Figure 6e. This Hyper-CEST effect map is obtained by post-processing the off- 
and on-resonant xenon MR images according to: Hyper-CEST effect map = (off-resonant – 
on-resonant)/off-resonant × 100
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS:
This research was supported by the NIH (R01-EB018975 to MGS), DARPA (W911NF-14–1-0111 to MGS), CIHR 
(Grant # to FSF) and HFSP (RGP0050 to MGS and LS). A.L. is supported by the NSF graduate research fellowship 
(award number 1144469). A.F. is supported by the NSERC graduate fellowship. S.P.N. is supported by the Caltech 
Summer Undergraduate Research Fellowship. D.M. is supported by the HFSP Cross-Disciplinary Postdoctoral 
Fellowship. Research in the Shapiro laboratory is also supported by the Heritage Medical Research Institute, the 
Burroughs Wellcome Fund, the Pew Charitable Trust, the Sontag Foundation and the David and Lucile Packard 
Lakshmanan et al. Page 47
Nat Protoc. Author manuscript; available in PMC 2018 October 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Foundation. Research in the Schröder laboratory is also supported by the Michael J. Fox Foundation for Parkinson’s 
(grant agreement no. 12549) and a Koselleck Grant by the German Research Foundation (DFG; project SCHR 
995/5–1).
REFERENCES:
1. Ferrara K, Pollard R & Borden M Ultrasound microbubble contrast agents: fundamentals and 
application to gene and drug delivery. Annu. Rev. Biomed. Eng 9, 415–47 (2007). [PubMed: 
17651012] 
2. Kaufmann BA & Lindner JR Molecular imaging with targeted contrast ultrasound. Curr. Opin. 
Biotechnol 18, 11–6 (2007). [PubMed: 17241779] 
3. Weissleder R et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of 
contrast agents for MR imaging. Radiology 175, 489–493 (1990). [PubMed: 2326474] 
4. Lee J-H et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. 
Nat. Med 13, 95–99 (2007). [PubMed: 17187073] 
5. Caravan P, Ellison JJ, McMurry TJ & Lauffer RB Gadolinium (III) chelates as MRI contrast agents: 
structure, dynamics, and applications. Chem. Rev 99, 2293–2352 (1999). [PubMed: 11749483] 
6. Walsby AE Gas vesicles. Microbiol. Rev 58, 94–144 (1994). [PubMed: 8177173] 
7. Pfeifer F Distribution, formation and regulation of gas vesicles. Nat. Rev. Microbiol 10, 705–15 
(2012). [PubMed: 22941504] 
8. Shapiro MG et al. Biogenic gas nanostructures as ultrasonic molecular reporters. Nat. Nanotechnol 
9, 311–316 (2014). [PubMed: 24633522] 
9. Maresca D et al. Nonlinear ultrasound imaging of nanoscale acoustic biomolecules. Appl. Phys. Lett 
110, 073704 (2017). [PubMed: 28289314] 
10. Cherin E et al. Acoustic Behavior of Halobacterium salinarum Gas Vesicles in the High-Frequency 
Range: Experiments and Modeling. Ultrasound Med. Biol 43, 1016–1030 (2017). [PubMed: 
28258771] 
11. Shapiro MG et al. Genetically encoded reporters for hyperpolarized xenon magnetic resonance 
imaging. Nat. Chem 6, 629–634 (2014). [PubMed: 24950334] 
12. Hane FT et al. In vivo detection of cucurbit [6] uril, a hyperpolarized xenon contrast agent for a 
xenon magnetic resonance imaging biosensor. Sci. Rep 7, (2017).
13. Barskiy DA et al. NMR Hyperpolarization Techniques of Gases. Chem. Eur. J, (2016).
14. Lakshmanan A et al. Molecular Engineering of Acoustic Protein Nanostructures. ACS Nano 10, 
7314–7322 (2016). [PubMed: 27351374] 
15. Li N & Cannon MC Gas vesicle genes identified in Bacillus megaterium and functional expression 
in Escherichia coli. J. Bacteriol 180, 2450–8 (1998). [PubMed: 9573198] 
16. Gilad AA & Shapiro MG Molecular Imaging in Synthetic Biology, and Synthetic Biology in 
Molecular Imaging. Mol. Imaging Biol, 1–6 (2017).
17. Zakeri B et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a 
bacterial adhesin. PNAS 109, E690–E697 (2012). [PubMed: 22366317] 
18. Schröder L, Chapter 8 HyperCEST Imaging In Chemical Exchange Saturation Transfer Imaging: 
Advances and Applications, Pan Stanford Publishing: 2017; pp 121–158.
19. Schröder L, Chapter 17 - Xenon Biosensor HyperCEST MRI A2 - Albert, Mitchell S In 
Hyperpolarized and Inert Gas MRI, Hane FT, Ed. Academic Press: Boston, 2017; pp 263–277.
20. Nikolaou P et al. Near-unity nuclear polarization with an open-source 129Xe hyperpolarizer for 
NMR and MRI. PNAS 110, 14150–14155 (2013). [PubMed: 23946420] 
21. Witte C, Kunth M, Rossella F & Schröder L Observing and preventing rubidium runaway in a 
direct-infusion xenon-spin hyperpolarizer optimized for high-resolution hyper-CEST (chemical 
exchange saturation transfer using hyperpolarized nuclei) NMR. J. Chem. Phys 140, 084203 
(2014). [PubMed: 24588160] 
22. Witte C et al. Hyperpolarized xenon for NMR and MRI applications. JoVE, e4268–e4268 (2012).
Lakshmanan et al. Page 48
Nat Protoc. Author manuscript; available in PMC 2018 October 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
23. Kunth M, Witte C, Hennig A & Schröder L Identification, classification, and signal amplification 
capabilities of high-turnover gas binding hosts in ultra-sensitive NMR. Chem. Sci 6, 6069–6075 
(2015). [PubMed: 30090222] 
24. Kunth M, Witte C & Schröder L Continuous‐wave saturation considerations for efficient xenon 
depolarization. NMR Biomed. 28, 601–606 (2015). [PubMed: 25900330] 
25. Smith R & Peat A Growth and gas-vacuole development in vegetative cells of Anabaena flosaquae. 
Arch. Microbiol 58, 117–126 (1967).
26. Buchholz B, Hayes P & Walsby A The distribution of the outer gas vesicle protein, GvpC, on the 
Anabaena gas vesicle, and its ratio to GvpA. Microbiology 139, 2353–2363 (1993).
27. Simon RD Morphology and protein composition of gas vesicles from wild type and gas vacuole 
defective strains of Halobacterium salinarium strain 5. Microbiology 125, 103–111 (1981).
28. Kunth M, Witte C & Schröder L Quantitative chemical exchange saturation transfer with 
hyperpolarized nuclei (qHyper-CEST): Sensing xenon-host exchange dynamics and binding 
affinities by NMR. J. Chem. Phys 141, 194202 (2014). [PubMed: 25416884] 
29. Zaiss M, Schnurr M & Bachert P Analytical solution for the depolarization of hyperpolarized 
nuclei by chemical exchange saturation transfer between free and encapsulated xenon 
(HyperCEST). J. Chem. Phys 136, 144106 (2012). [PubMed: 22502500] 
Lakshmanan et al. Page 49
Nat Protoc. Author manuscript; available in PMC 2018 October 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
BOX 1 | GENERAL SIGNAL CONSIDERATIONS ● TIMING 5 m
In comparison to 1H MRI, the concentration of Xe is approximately 5 orders of 
magnitude lower. This is compensated by its higher polarization, approximately 4 orders 
of magnitude. Hence, higher Xe partial pressure helps to increase the detectable signal, 
which is directly proportional to the xenon concentration in solution. The calculation to 
determine the Xe concentration in solutions can be done as follows using the Ostwald 
solubility coefficient:
1. For the phosphate-buffered saline solution, assume an Oswald solubility 
coefficient similar to that of water: 0.11 L/bar or 4.9 mM/bar (1 mole of an 
ideal gas corresponds to 22.41 L). The partial pressure of the Xe fraction (5%) 
for 1.2 bar of gas mixture in the system is then 0.05 × 1.2 bar and the 
concentration of dissolved Xe is [Xe] = 0.11 L/bar × 0.05 × 1.2 bar × 4.9 
mM/bar = 295 μM (keep in mind that only 26.4% is NMR-active isotope 
129Xe).
2. To get an idea how long it takes to saturate the solution with Xe, consider the 
following: It has been shown that bubbling water with a 2% Xe mix at a flow 
corresponding to 100 SMLM (calibrated to N2, i.e. ca, 140 SMLM 2% Xe 
mix) exponentially saturates the solution with Xe with a time constant of ca. 8 
sec (see supplementary information of ref. [23]). A 5% Xe mix at 40 SMLM 
(described in this protocol) delivers ca. 29% less Xe per unit time, and the 
time constant increases accordingly.
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Box 2|FLIP ANGLE CALIBRATION FOR HYPERPOLARIZED XENON ● 
TIMING 10m
Flip angle calibration is usually done with a series of repetitive excitations and 
subsequent analysis of the obtained signal intensities. It is used to derive pulse 
amplitudes for the shaped excitation pulses but also to determine the saturation power in 
μT. Since hyperpolarization does not self-replenish, it is convenient to use a constant 
small flip angle excitation and analyze the signal decay after a single Xe delivery as 
follows:
ADDITIONAL MATERIALS
• Non-selective NMR pulse sequence for acquiring a series of Xe solution 
signals after a single Xe delivery. This is implemented by using a simple 
(pulse – acquire – crusher) sequence with fast repetition between the 
excitations. As an example, the sequence can have a 100 μs block excitation 
pulse of adjustable amplitude, followed by a 9.72 ms FID sampling time (99 
data points collected) and crusher gradients to remove all remaining 
transverse magnetization.
• Evaluation tool like a gnuplot fitting routine or Origin to fit the data to a user-
defined exponential decay model function.
PROCEDURE
1. Choose the above-mentioned non-selective NMR sequence with single Xe 
delivery and multiple acquisitions.
2. Select a relatively small excitation pulse amplitude (assuming α~ 7° – 11°).
▴CRITICAL STEP If the amplitude is too high, the signal decay will be 
either too fast or not monotonous; if the amplitude is too low, the observed 
signal is too noisy over the entire series.
3. Run the sequence with a repetition time of 18 ms and NEX = 250 repetitions; 
the crusher gradients burn for ca. 1 ms at an amplitude of ca. 90 G/cm.
4. The incoming time domain signal will show a series of 250 truncated FID 
signals. The spectrometer software may display this as a series of 250 FT 
magnitude spectra with decaying signal intensity (Figure 6f-g). For an 
evaluation without custom-made scripts like gnuplot fitting routine, perform 
the following steps:
5. Export the magnitude spectra data as .txt file and load them into Origin.
6. Perform ParaVision standard post-processing: each spectrum contains 128 
data points of which only the peak heights are important.
7. Plot the concatenated spectra and evaluate the envelope formed by the peak 
heights. This envelope can be reconstructed with the υAnalysis υSignal 
Processing υEnvelope tool in Origin with using ca. 100 smoothing points.
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8. Fit the envelope using the function I(x) = M0 + I0 sin α (cos α)(x/p - 1) with α 
as the desired unknown flip angle, M0 as a constant offset representing the 
non-vanishing noise level for large x, p the fixed number of displayed data 
points between two peaks. The fit should be performed for the range where 
the actual data is still above the noise level (Figure 6h-i). This evaluation 
neglects T1 relaxation during the short acquisition time. Fitting the observed 
signal intensity to this function therefore yields the flip angle α that the 100 
μs block pulse achieved for the selected pulse amplitude.
9. The scaling factor for the pulse amplitude of a 10-fold longer standard block 
pulse (1 ms) is then given by 90°/(10*α). Use this for the reference gain for 
all derived pulse amplitudes.
10. Knowing the amplitude for a 90° pulse of 1 ms length, derive the pulse power 
in μT as follows: a full nutation takes 4 ms, hence the precession about the B1 
field occurs at 250 Hz. The gyromagnetic ratio for 129Xe is γ = 11.777 
kHz/mT. Hence, the applied field strength is B1 = 250/11,777 mT = 0.0212 
mT = 21.23 μT. This can be used to derive the pulse powers for a desired 
saturation level in μT.
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Figure 1. Flowchart illustrating the experimental design and workflow for gas vesicle (GV) 
production, quantification, characterization, functionalization and imaging applications.
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Figure 2. Equipment setup and expected results for native production and purification of GVs.
(a-b) Shaker-incubators adapted for the growth of cyanobacteria Anabaena flosaquae 
providing controlled illumination, temperature, aeration and CO2. (c-d) Confluent green and 
pink cultures of Anabaena flosaquae and Halobacteria salinarum respectively, just before 
harvesting. (e-f) Effective separation of buoyant cells from spent media in separatory funnel 
for isolation and harvesting of Ana and Halo cells producing GVs. Purified Halo (g) and 
Ana (h) and Mega (i) GVs as a dense milky-white layer post centrifugally assisted 
floatation. (j) Resuspended milky-white solutions of purified Ana (left), Halo (middle) and 
Mega (right) GVs in PBS at OD500,ps ~6 prior to use in ultrasound imaging experiments.
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Figure 3. Collapsometry setup.
Illustration of the collapsometry setup used for determining the critical collapse pressure of 
GVs.
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Figure 4. Ultrasound setup for in vitro and in vivo imaging.
(a) Setup of the in vitro imaging system with the Verasonics L11–4v transducer mounted on 
a 3-D translatable clamp (computer-controlled) and a fixed imaging phantom holder. Inset 
shows an agarose phantom loaded with GV and polystyrene samples prior to imaging. (b) In 
vivo imaging setup with the Verasonics L22–14v transducer, mounted on a 3-D positioning 
system (manual), an animal mounting platform with a heating pad and a syringe pump for 
controlled sample injections. (c) Setup of the Vevo imaging station includes the ultrasound 
probe clamp attached to the 3D stepper, the mouse handling table and the physiological 
monitoring unit. All components except the physiological monitoring unit are attached to the 
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bench-top rail system. (d) Animal positioning with the mouse being laid down in a supine 
position with the nose and mouth in the nose cone and each paw extending outwards onto 
the electrodes and secured with surgical tape. A rectal probe is used to monitor the core 
temperature of the animal.
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Figure 5. Required elements for assembling the gas delivery manifold for 129Xe-MRI.
(a) Main glass phantom made from 10 mm thick wall NMR tube and chem thread 
connectors; PFA tubings are connected with a chem thread srew cap and an O‐ring. (b) Glass 
tube connector. This is also used for step 3, but mainly for connecting the PFA tubing with 
the capillary holder. (c) Capillary holder. (d) PhotoMOS circuit for controlling the solenoid 
valve. (e) Schematics of the communication between the NMR pulse sequence and the gas 
delivery manifold with corresponding tube and electrical connections.
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Figure 6. 129Xe HyperCEST MRI.
(a) 1D 129Xe NMR spectrum of a solution containing GVs, illustrating the signal from Xe 
gas in the space above the sample solution (magenta), the below-the-noise signal from GV-
bound Xe (yellow) and the signal from the dissolved Xe in solution (cyan), which is 
assigned to 0 ppm for referencing. (b) Hyper-CEST z-spectrum of Mega GVs (0.67 nM in 
PBS, T = 295 K). On-resonant (- 156.5 ppm) and off-resonant (+ 156.5 ppm) saturation (B1 
= 15 μT, tsat = 5 s) produced different signal intensity, and the spectrum was fitted to the 
exponential of two Lorentzian line shapes,. Analysis based on Bloch-McConnell equations 
predicts that the GV-bound Xe resonance frequency (green dashed line) is about −170 ppm. 
(c-d) Axial off- and on-resonant saturation xenon MR image (16 times averaged). A 5 mm 
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NMR tube containing Mega GVs is nested inside a 10 mm NMR tube containing only PBS. 
(e) The differential images is normalized by the intensity of the off-resonant image and 
demonstrates the ~ 50 % Hyper-CEST contrast of GVs. The white dashed circles indicate 
the glass walls of the double-tube phantom. (f-i) Flip angle calibration. (f) Full time-domain 
FID signal train of 250 acquisitions (black: real domain, and red: imaginary) showing an 
overall exponential decay (bold solid lines) that is regularly interrupted by the ringing 
artefacts of opening the ADC gate. (g) Zoom-in of the first four FIDs. (h) Concatenated 
magnitude spectra after Fourier transforming the data displayed in (f). The fitting (green 
line) is based on the first 100 spectra, giving α = 12.6°. (i) Zoom-in for the first 10 spectra.
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Figure 7. Anticipated results for GV characterization and in vitro ultrasound imaging
(a) Coomassie stained SDS-PAGE gel indicating complete removal of native GvpC (ΔGvpC, 
lane 2) and re-addition of two recombinant GvpC variants, GvpCWT and ΔN&C GvpC 
(lanes 3 and 4). The smeared bands around 250 kD represent GvpA polymers forming the 
inner GV scaffold whereas GvpC bands are visible at lower molecular weights. (b) Confocal 
fluorescence image showing dual-functionalized Ana GVs with RGD peptide and Alexa 
Fluor-488 (green) after a 24 h incubation with U87 glioblastoma cells (DAPI-stained nuclei, 
blue). Scale bars are 50 μm. (c) Dual-mode imaging of GVs functionalized with SpyCatcher-
mNeonGreen with ultrasound (top panel) and fluorescence (ex 506 nm, em 550 nm) (bottom 
panel). Scale bars are 1 mm. Figures (b) and (c) adapted with permission from Lakshmanan, 
A. et al. Molecular Engineering of Acoustic Protein Nanostructures, ACS Nano, Copyright 
© 2016, American Chemical Society. (d) Collapse pressure profiles for GV variants (Halo, 
Mega, Ana ΔGvpC and Ana GvpCWT). (e) DLS measurements showing typical size 
distributions for purified Halo, Mega, ΔGvpC and GvpCWT Ana GVs (f) Representative 
TEM images for purified Halo, Ana and Mega GVs. Scale bars are 200 nm. (g) TEM 
showing intact and collapsed Ana GVs. Scale bars are 200 nm. Figure (g) adaptedwith 
permission from Shapiro, M.G. et al. Biogenic gas nanostructures as ultrasonic molecular 
reporters, Nature Nanotechnology, Copyright © 2014, Nature Research Group.
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Figure 8. Anticipated results for in vitro and in vivo ultrasound imaging.
(a) Fundamental and second harmonic images for intact ΔGvpC and GvpCWT Ana GVs (top 
panel) acquired using the Verasonics L11–4v transducer with a 4.46 MHz transmission and 
band-pass filtered around 4.46 and 8.92 MHz respectively. A high power burst from the 
transducer is used to collapse the GVs (bottom panel). Scale bars are 1 mm. (b) B-mode 
image of the liver showing the (i) inferior vena cava (IVC), (ii) portal vein and (iii) 
abdominal aorta. Contrast mode images acquired using high-frequency ultrasound show the 
liver and IVC with the baseline contrast image before injection of Halo gas vesicles. 
Following a bolus injection of gas vesicles, contrast enhancement is seen in the IVC 
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followed by the liver. (c) Time intensity curve depicting the nonlinear contrast signal change 
over time for the IVC (orange) and the liver (blue) before, during, and after an intravenous 
administration of Halo gas vesicles. Time intensity curve in the (d) fundamental and (e) 
second harmonic mode depicting the change in acoustic signal in the IVC before, during and 
after steady infusion with ΔGvpC and GvpCWT Ana GVs. Shaded regions represent SEM 
(N=6).Figures (a, d-e) adapted with permission from Lakshmanan, A. et al. Molecular 
Engineering of Acoustic Protein Nanostructures, ACS Nano, Copyright © 2016, American 
Chemical Society.
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Table 1:
Characteristics of different types of GVs
Ana GV Halo GV Mega GV
Host/origin Anabaena flosaquae Halobacteria salinarum Heterologous expression of a gene cluster 
from Bacillus megaterium in E. coli.
Shape Cylindrical Spindle Cylindrical
Resistance to pressure-induced collapse Medium (can be tuned) Low High
Ultrasound contrast High
Nonlinear after engineering
High
Nonlinear
Low
Stability in Xe-MRI phantoms High Low High
Ease of genetic modification High Low Not established
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Table 2:
Experimental Parameters for GV Production, Purification and Storage
Procedure Design Parameters
Inoculation of starter culture Type of culture (suspension vs. solid), amount of inoculum, total volume of culture
Growth of starter culture Temperature, rotation speed, duration, illumination
Sub-culturing Number of flasks, volume of culture and media
Harvesting of GVs Composition of lysis buffer and duration of lysis, concentration of cells
Purification Selection of centrifugation speed, type of rotor, tube and syringe needle
Storage Storage temperature, buffer and type of vial/tube
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Table 3.
Quantification and calculation of GV molecular weight and molar concentration.
Ana Halo Mega
Protein concentration to OD500 ratio ([μg/mL] / OD) 36.6 ± 2.6 13.4 ± 2.2 145.5 ± 6.4
Estimated molecular weight (MDa) 320 282 71.7
Estimated molar protein concentration to OD500 ratio (pM / OD) 114 47.3 2,030
Estimated gas fraction to OD500 ratio (v/v/OD) 0.000417 0.000178 0.000794
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Table 4:
GV Dimensions
Spatial Dimension Ana GV Halo GV Mega GV
Length (nm) 519 ± 160 400 ± 113 249 ± 99
Width (nm) 136.3 ± 21.0 250.8 ± 51.4 72.5 ± 13.6
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Table 5.
Troubleshooting Table
Step No. Problem Possible Reason Solution
1A(iv), 1A(vi) 1B(iii) Cultures growing too slowly Not enough viable cells Increase the amount of starter 
inoculum.
1A(iv), 1A(vi) 1B(iii) Cell death Contamination Start fresh from primary cultures 
and follow sterile procedures.
Incubator conditions (aeration, pH, 
temperature and lighting) not optimal
Loosen the cap/foil to allow 
aeration, monitor CO2 levels. 
For Ana cultures, ensure 
temperature inside incubator 
does not increase during light 
cycle due to heat from the lamps 
and confirm proper exposure of 
the cultures to light.
1A(vii)-(xi), 1B(iv)-(vi) Poor GV yield Cultures not confluent Allow cultures to grow for a few 
more days. Confluency is 
determined by the color and 
turbidity of the cultures as 
described in the procedure and 
shown in Figure 2
1A(xi), 1B(vi) Incomplete lysis Dilute the concentrated cell 
suspension with lysis buffer 
and/or allow lysis to proceed 
longer.
1A(vii)-(xi), 1B(iv)-(vi) Collapse of GVs Make sure the cultures are not 
subjected to agitation above 100 
rpm and handle flasks gently 
while transporting and placing 
on hard surfaces.
1A(x), 1B(vi) Inefficient retrieval of buoyant cells from the 
separatory funnel
Thoroughly wash the inner walls 
of the funnel with media/buffer 
to retrieve the buoyant cells 
sticking to the sides (especially 
for Halo).
1A(xii) Incomplete separation of GVs 
from lysate/subnatant
Lysate is too dense, requiring longer spins 
for GVs to float to the top
Increase time of centrifugation 
and/or dilute lysate with PBS 
prior to spin
1A(xii), 1C(v) Collapse of GVs during spins Hydrostatic Pressure on GVs greater than 
critical collapse pressure
Aliquot suspensions into more 
tubes to reduce height of the 
column (volume in a single 
falcon tube should not exceed 40 
mL).
1A(xv), 1B(vii) Pressurization of tubes while opening and 
closing
Ensure microcentrifuge tubes 
are closed very gently. The caps 
of such tubes should not make a 
snap sound when closed.
8 NHS-amine reaction did not 
work
NHS will hydrolyze in the presence of 
water/moisture.
Ensure DMSO used for storage 
is anhydrous.
Limit exposure to ambient 
moisture.
Store in a desiccated 
environment.
4-10 GVs aggregate after reaction 
with NHS-moiety
Conjugation of moieties on the GVs 
destabilizes the protein.
Conjugate fewer moieties on the 
GV surface by reducing the 
concentration of NHS-moiety 
and/or reaction time.
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Step No. Problem Possible Reason Solution
Presence of surfactants in the reactant 
sample.
Purify the NHS-moieties using 
chromatography or other 
methods.
9, 10 Subsequent reaction using 
NHS-moiety conjugated GVs 
does not work.
Presence of excess NHS-moieties in 
solution.
Repeat dialysis until excess 
NHS-moieties are below level of 
detection.
11-19 Incomplete GvpC stripping GV concentration is too high for efficient 
removal of GvpC
Dilute native Ana GVs in PBS 
to an OD ~ 5 before adding 10 
M urea buffer.
20-38 Low or no GvpC yield Low expression of GvpC variant Check plasmid for mutations, 
prepare fresh transformations 
and try reducing temperature 
and increasing duration of 
expression.
Poor binding to the Ni column Ensure column is charged and 
increase incubation time with 
resin or add more resin.
Inefficient retrieval of inclusion bodies Ensure that inclusion pellets are 
not lost during repeated rounds 
of centrifugation and 
resuspension
39-41 Incomplete GvpC re-addition GV concentration is too high for re-addition 
reaction to go to completion
Reduce GV OD500 during GvpC 
re-addition. Confirm re-addition 
by SDS-PAGE and Coomassie 
staining.
GvpC concentration is too low Inaccurate quantification of 
GvpC eluate.
39-41 Protein precipitation is seen 
after re-addition
Excess unbound GvpC forms precipitates in 
PBS.
Reduce stoichiometric excess 
factor of GvpC during re-
addition.
42-45 No fluorescence from 
SpyCatcher-GFP-labeled GVs
Incomplete SpyTag functionalization Confirm GvpC-SpyTag re-
addition using SDS-PAGE.
Incomplete SpyTag-SpyCatcher reaction Increase excess factor of 
SpyCatcher during reaction 
and/or increase reaction time.
46A Collapse curves are inconsistent 
or noisy
Incomplete collapse Make sure that there are no air 
leaks in the connectors or 
bubbles in the sample
Presence of detergents and/or incomplete 
GvpC addition
Always run control GV samples 
such as ΔGvpC and GvpCWT to 
ensure that the re-addition was 
done under proper conditions 
and corroborate with SDS-
PAGE results.
46C Too much black background on 
TEM grid
GV sample contains contaminants or 
phosphate-containing molecules
Using dialysis or centrifugally-
assisted purification to 
resuspend GVs in 10 mM 
HEPES with 150 mM NaCl 
buffer.
Uranyl acetate precipitate present in solution Avoid extended exposure to 
ambient light. Uranyl acetate 
will precipitate when exposed to 
light and UV.
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Step No. Problem Possible Reason Solution
46C Too many or too few GVs on 
the TEM grid
Incorrect GV OD measurement Measure GV OD and double 
check the dilution calculation.
GVs were not given adequate time to adhere 
on charged grids.
Excessive wicking can cause too 
many GVs to come off grids. 
Reduce how much solution is 
being wicked off.
47-62 Only the top of the GV sample 
for in vitro ultrasound 
phantoms shows contrast
The concentration of GVs is too high. Lower the concentration of GVs.
47-62 The signal from GVs and 
polystyrene beads is very 
different.
The concentration of GVs or polystyrene 
beads is too high or too low.
Matching of GVs’ concentration 
to concentration of beads.
63A, 63B Weak or no signal after 
injection
IVC not in the image Move the transducer to find the 
optimal location in the IVC and 
try to align the imaging target 
with the natural focus of the 
transducer
GVs collapsed prior to or during injection Check that there is no pressure 
when injecting through the 
catheter by manually injecting a 
small volume of saline with a 
30G syringe. If you feel 
pressure, readjust the catheter 
into the tail vein and ensure that 
there are no blocks, allowing the 
saline to flow smoothly
Transmit power set too high Ensure that transmit power does 
not generate an acoustic 
pressure on the GVs that 
exceeds the critical collapse 
pressure
82 Excessive foam formation The overall protein concentration in the 
sample is too high
Reduce the protein 
concentration – or – add an 
antifoam agent such as pluronic 
L81 (ca. 0.1% by vol.); however, 
such an agent can also have an 
impact on the integrity of the 
protein structure
88 The Xe NMR spectrum does 
not show any signal or very 
distorted signals
The excitation pulse is too weak Increase the amplitude for the 
excitation pulse
The field homogeneity is poor Perform another shim
There are still gas bubbles in the sample 
while acquiring the FID signal
Increase the waiting time after 
bubbling or consider adding an 
antifoam agent
The Rb is oxidized and no hyperpolarized 
Xe is produced
Check the laser absorption 
profile of the hyperpolarizer and 
replace the Rb in the pumping 
cell if necessary
92A(v) No CEST response from the 
GVs is observed in the z-
spectrum, or the image with on-
resonant saturation does not 
really show a signal loss
GVs have collapsed Measure the OD of the sample 
and prepare a fresh one from 
stock solution if necessary
GV concentration too low Add GVs from stock solution
Saturation power too low or saturation time 
too short
Increase the saturation power or 
the saturation time
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Step No. Problem Possible Reason Solution
92A(v) The saturation response from 
the GVs is too broad and 
merges into the direct saturation 
response
Saturation power is too high Reduce the saturation power
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